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This thesis focuses on depression during pregnancy (or antepartum depression), 
with a special focus on the effects of light, seasons and sleep. In the next paragraphs 
of this introduction, a brief overview of depression and depression specifically during 
pregnancy will be provided, followed by the focus of the different parts of this thesis, 
study populations, outline and aims of this thesis. 
 
Depression 
Depression is a serious mood disorder with the highest disease burden worldwide, 
according to the World Health Organization [1]. It is estimated that 4.4% of the global 
population suffers from depression, with females being more often affected than men 
[1]. According to the Diagnostic and Statistical Manual of Mental Disorders, fifth 
edition (DSM-5), depression is characterized by a depressed mood and/or 
anhedonia, for a minimal duration of two weeks. In addition, patients experience at 
least three or four of the following symptoms: significant weight loss or gain or 
significant changes in appetite, insomnia or hypersomnia, psychomotor agitation or 
retardation, fatigue, feelings of worthlessness and/or guilt, diminished ability to think 
and/or concentrate or recurrent thoughts of death with potential suicidal ideation or 
even attempts [2].  
The cause of depression is largely unknown. Since hyperactivity of the 
hypothalamus-pituitary-adrenal gland (HPA) axis is associated with depression, it is 
thought that this axis plays a crucial role in the pathophysiology – as cause or 
consequence. Depression is thought to be related to a reduced inhibition of the HPA 
axis feedback loop by cortisol, due to impaired functioning of the glucocorticoid 
receptor (GR) [3]. Figure 1.1 shows a schematic overview of the feedback loop of 
cortisol.  
The HPA axis regulates secretion of cortisol in response to stress [4]. HPA axis 
activity is controlled by the corticotropin-releasing factor (CRF) secreted by the 
paraventricular nucleus (PVN) of the hypothalamus. CRF activates the anterior 
pituitary to produce and secrete adrenocorticotrophic hormone (ACTH), which in turn 
stimulates the production and release of cortisol from the adrenal cortex [3, 4]. 
Cortisol inhibits both CRF and ACTH through the GR [3, 4]. In patients with 
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depression, this feedback loop is dysregulated, resulting in increased basal cortisol 
levels [3]. 
 
 
 
 
Figure 1.1 – Schematic overview of the hypothalamus-pituitary-adrenal gland (HPA) 
axis. 
PVN = paraventricular nucleus; GR = glucocorticoid receptor; CRF = adrenocorticotrophic hormone 
releasing factor; ACTH = adrenocorticotrophic hormone;+ = stimulating; − = inhibiting 
 
Depression during pregnancy 
Contrary to earlier beliefs, pregnancy does not protect the mother from depression. 
A systematic review of 96 articles showed that approximately 12% of pregnant 
women suffer from depression [5]. Women who suffer from antepartum depression 
have a higher risk of postpartum depression as well [6]. According to the DSM-5, 
postpartum depression (often incorrectly stated as ‘postnatal depression’) has an 
onset within four weeks after delivery [2], but clinicians often use a broader definition 
in practice, such as six months or even a year postpartum [7]. However, a 
considerable proportion of women with postpartum depression has an onset during 
pregnancy or even before conception [8].  
Many risk factors for antepartum depression have been identified, such as history of 
depression, fear of childbirth, lack of social support and low socio-economic status 
[9, 10]. 
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Maternal depression during pregnancy has been associated with various adverse 
birth outcomes, such as prematurity and being small for gestational age [11, 12]. 
Additionally, children show more often cognitive, emotional and behavioral problems 
in childhood, adolescence and adulthood [13] and they are more at risk of suffering 
from depression themselves [14]. How intra-uterine child development is influenced 
by maternal depression has yet to be determined. Possible mechanisms are 
maternal cortisol crossing the placenta, placental secretion of CRF, which stimulates 
both maternal and fetal cortisol, and reduced blood flow to the fetus, causing fetal 
growth restriction [11, 15-18]. Increased maternal levels of cortisol might program 
the intra-uterine developing HPA axis of the child, making it susceptible to increased 
stress reactivity in future life [13, 19]. Moreover, maternal cortisol can directly 
influence fetal brain development, such as that of the amygdala and the 
hippocampus [20-23]. Additionally, other intra-uterine factors that are indirectly 
associated with maternal depression, such as unhealthy nutrition [24] and substance 
use [25], may affect fetal development. Finally, genetic factors and postpartum 
environmental factors could contribute to the higher risk of cognitive, emotional and 
behavioral problems in offspring [26, 27].  
The peripartum period is thus a critical time period, in which fetal development 
determines not only the health of the (unborn) infant, but also that of following 
generations [28]. Therefore, early detection and treatment of antepartum depression 
is critical for both mother and infant. 
 
Light therapy 
In non-pregnant patients, guidelines propose psychotherapy, antidepressant 
medication or a combination of both as treatment for depression. However, clinical 
practice shows limited relevance of these guidelines for the treatment of depression 
during pregnancy, as psychotherapists are not always directly available, postponing 
treatment for several months or more, which may result in the child not benefitting 
from the maternal treatment. Other limitations with psychotherapy are motivation to 
reflect on behavior and emotions and good language skills, which both limits the 
applicability of psychotherapy in these patients, considering the majority of these 
women have a lower socioeconomic background and other problems that interfere 
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with compliance [29]. Therefore, women may be treated with antidepressant 
medication. In the Netherlands, approximately 2-3% of pregnant women use 
antidepressants [30-32]. In the United States, this prevalence is approximately 6-7% 
[33-35], but this could even be as high as 15% in some states [36]. However, the 
use of antidepressants is still controversial, due to potential harmful fetal effects [37, 
38]. For example, increased risks have been found for cardiovascular malformations 
[39], persistent pulmonary hypertension of the neonate [40] and preterm delivery and 
low birth weight [41]. Additionally, international guidelines in the pharmacological 
treatment of antepartum depression are not always consistent [42] and adherence 
to national guidelines is low [43], which could possibly result in unwanted variation 
in current practice. Despite this, antidepressant use during pregnancy is increasing. 
Not only in the Netherlands [32, 44], but in other European countries and the United 
States as well [45-47]. Therefore, it is urgent to investigate alternative approaches 
to treat antepartum depression, such as bright light therapy (BLT). The efficacy of 
light therapy in treating non-seasonal depression has been shown by a Cochrane 
review [48] and more recent systematic reviews and meta-analyses [49-52]. An open 
trial of BLT in pregnant women showed improvement of mean depression ratings by 
49% [53]. Two small randomized controlled trials (RCTs) showed significant 
improvement of depressive symptoms among pregnant women exposed to BLT 
compared to placebo [54, 55]. Although these studies provide evidence for the 
effectiveness of BLT for depression during pregnancy, their sample size is small and 
follow up was limited to the end of the intervention period.  
In this thesis, we aimed at studying a larger sample size to study whether BLT is an 
effective and safe treatment for antepartum depression. Additionally, women were 
followed up until eighteen months postpartum. 
So how does light therapy work? Light is the most powerful environmental stimulus, 
or ‘zeitgeber’, that synchronizes the suprachiasmatic nucleus (SCN), also known as 
the ‘biological clock’, with the environmental day-night rhythm [56]. Light hits the 
retina and intrinsically photosensitive retinal ganglion cells (ipRGCs), which are the 
output neurons of the retina, project via the retino-hypothalamic tract to the SCN, 
and thus influencing circadian rhythm [56-58], which may indirectly benefit 
depressive symptoms [59]. However, not only do ipRGCs project to the SCN, they 
also project to other brain regions, such as the medial amygdala and the lateral 
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habenula, which are important brain regions in the regulation of mood, and thus 
directly influencing depressive symptoms [56-58]. 
The SCN controls the HPA axis, which is seen in the association between decreased 
inhibitory control of the SCN and HPA axis hyperactivity [60]. Light synchronizes the 
SCN with the environmental day-night rhythm, influencing the HPA axis and thus 
cortisol levels. Next to cortisol, light also influences the circadian rhythm of melatonin 
[61-63]. 
 
Seasons 
The effects of BLT have been shown in non-seasonal depression [48-52], but was 
first used as a treatment for seasonal affective disorder (SAD), a condition of 
reoccurring depressions during fall and winter, with remissions in spring and summer 
[64, 65]. In 1984, the first cases of SAD have been described by Rosenthal and 
colleagues, together with preliminary findings on treatment with light therapy [66]. 
However, in contrast, some SAD cases are not characterized by depressive 
episodes during autumn and winter, but during spring and summer [67, 68]. 
Seasonal variability has also been found in depressive symptoms during pregnancy 
[69] and after pregnancy in the postpartum period [70-75]. However, seasonality in 
postpartum depressive symptoms has not been shown by all studies [76-78]. These 
different findings may be explained by geographical location (and with that latitude), 
method of assessment (such as the use of specific questionnaires) and other 
characteristics of the study. 
Since SAD and light therapy are intertwined to a high extent, we studied the 
seasonality of depressive symptoms during pregnancy in this thesis. We 
hypothesized that if seasons influence depressive symptoms during pregnancy, it 
might possibly influence the treatment effect of light therapy in the Bright Up study. 
 
Sleep 
As mentioned earlier, there are many risk factors for antepartum depression. 
Additionally, pregnant women typically show disturbed, desynchronized circadian 
rhythms, resulting in disturbed sleep patterns, which put them at risk for depression 
[79]. This is partly due to various hormonal changes. Increased estrogen and 
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progesterone levels during pregnancy influence normal sleep patterns: the increase 
in estrogen levels reduces rapid eye movement (REM) sleep, whereas progesterone 
increases non-REM sleep [80, 81]. Cortisol levels increase in pregnancy, which may 
affect sleep as well [81, 82]. Additionally, women may find it difficult to find a 
comfortable sleeping position as the pregnancy progresses [83]. Moreover, restless 
leg syndrome is common during pregnancy and may also contribute to sleep 
problems [80, 84]. Finally, frequent nocturnal bathroom visits may affect sleep as 
well [80].  
Poor sleep quality during pregnancy is associated with both antepartum and 
postpartum depressive symptoms [85-89], although a causal relation is difficult to 
prove due to the reciprocal relation of depression and sleep. However, evidence 
suggests that sleep problems precede depressive symptoms in the peripartum 
period [90-92]. 
Light has not only a major direct effect on mood as discussed earlier, but also on 
sleep, which may indirectly benefit mood as well [57]. The ipRGCs also project to 
the ventrolateral preoptic area and the lateral hypothalamus, which are important 
brain regions in the regulation of sleep [57, 58]. Moreover, these brain regions 
receive input from the SCN as well [57]. Further, the SCN, which is influenced by 
light, controls the circadian rhythm of melatonin, which is important in sleep [63]. 
Light therapy may therefore be effective in treating sleep problems [93].  
Due to this reciprocal relation between mood and sleep and due to the tremendous 
effects of BLT on sleep [57], we dedicated a part of this thesis to sleep. In this part, 
we studied the effects of sleep during pregnancy and the use of benzodiazepines 
during pregnancy, which are often prescribed for sleep problems. 
 
Study populations 
Women who were included in the studies described in this thesis originated from the 
following cohorts: 
 
The Bright Up study 
This RCT studies the effectiveness of BLT for pregnant women with a depressive 
disorder. The inclusion criteria were 12-32 weeks of pregnancy and a DSM-5 
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diagnosis of major depressive disorder. The exclusion criteria were amongst others 
primary anxiety disorder, earlier treatment with BLT and multiple pregnancy. 
Participants were either referred by midwives, gynecologists, general practitioners 
or mental health care workers or they signed up themselves without referral from a 
professional. Recruitment took place in The Netherlands from November 2016 to 
March 2019.  
After inclusion, women were randomized in two treatment arms: BLT or dim red light 
therapy (DRLT). Although it is not known which of these two are more effective, we  
hypothesize that the DRLT condition can be considered as placebo. After receiving 
the lamps, participants commenced their daily treatment with light for 30 minutes 
within 30 minutes of habitual wake up time for six weeks. Follow up took place until 
eighteen months postpartum. Primarily, we collected data on the effects of BLT and 
DRLT on depressive symptoms during pregnancy. Secondly, we collected data on 
the effects on sleep quality and melatonin and cortisol levels. Finally, we collected 
data on various birth and child outcomes. 
The complete protocol for the Bright Up study can be found in Chapter 2. Chapter 
3 discusses the results regarding the primary research question. 
 
The Mind2Care study 
This study is an observational cohort aimed at identifying women with 
psychopathology, psychosocial problems and substance abuse in routine obstetric 
care. Women attending an antenatal check-up at one of the participating midwifery 
practices and obstetric units were invited to fill out a digital screener, the Mind2Care 
questionnaire [94]. Women were eligible when they were pregnant. Exclusion criteria 
were having a miscarriage at the time of screening, insufficient proficiency in Dutch 
and insufficient mental capability to complete the questionnaire independently. Data 
collection for the study in this thesis took place mainly in rural and urban regions in 
the southwest of the Netherlands and in two cities in the south and east part of The 
Netherlands between April 2011 and December 2015. 
The findings of this study are discussed in Chapter 4. 
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The DAPPER study (Daycare Alternative Psychiatric Pregnant women Efficiency 
Research) 
This RCT aimed to evaluate the effectiveness of a group-based multicomponent 
psychotherapy intervention, developed and performed at the Erasmus University 
Medical Center in Rotterdam, The Netherlands, for pregnant women with a 
psychiatric disorder, compared to individual counseling (care as usual). Recruitment 
for this study took place between January 2010 and January 2013 at the tertiary 
outpatient clinic for perinatal psychiatry of the Department of Psychiatry, Erasmus 
University Medical Center. Women were eligible when they were diagnosed with a 
mental disorder and when they were 12-33 weeks pregnant. Exclusion criteria were 
an indication for hospital admission, inability to function in a group due to severe 
behavioral problems, insufficient proficiency in Dutch and being unable to visit the 
outpatient clinic.  
A subset of participants was recruited between 24 and 29 weeks of pregnancy for 
the study in this thesis, which is discussed in Chapter 5. 
 
National Centre for Register-based Research (Aarhus, Denmark) 
This population-based cohort study studies the prescription patterns of 
benzodiazepines and benzodiazepine-related drugs before, during and after 
pregnancy from 1997 to 2015 in Denmark. Here, all Danish individuals are registered 
in the Danish Civil Registration System through a unique personal civil registration 
number that enables individual-level linkage of information across nation-wide 
registries, such as the Medical Birth Registry and the National Prescription Registry. 
A major advantage of population-based cohort studies is that all residents are eligible 
for participation, which eliminates the risk of selection bias. 
The findings of the analyses in this population are discussed in Chapter 6. 
 
Outline and aims of this thesis 
This thesis aims to extend existing knowledge on depression during pregnancy, with 
a special focus on light, seasons and sleep. 
In Part I of this thesis, we focus on the effects of light therapy for antepartum 
depression. We present the extensive study protocol of the Bright Up study in 
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Chapter 2. Here, we will provide a study design of an RCT, studying the 
effectiveness of light therapy for depression during pregnancy. In Chapter 3, we 
present the findings of the primary research question of this study, namely whether 
BLT is effective for treating antepartum depression. 
Part II focuses on the seasonality of depressive symptoms during pregnancy, which 
will be discussed in Chapter 4. The aim of this study is to evaluate the seasonal 
influences of depressive symptoms in pregnancy. 
The aim of Part III is to gain more insight in the effects of sleep during pregnancy. 
Chapter 5 investigates the effects of sleep on depressive symptoms during 
pregnancy. Here, we will study both objective and subjective sleep quality and the 
effects on the course of antepartum depressive symptoms in psychiatric patients. 
Many pregnant women suffer from sleep problems, which may be treated with 
benzodiazepines or benzodiazepine-related drugs. Therefore, we also focus on 
these medications in this part of the thesis. In Chapter 6, we study the prescription 
patterns of benzodiazepines and benzodiazepine-related drugs in the peripartum 
period. The aim of this chapter is to gain insight in the usage of these drugs before, 
during and after pregnancy in a population-based cohort in Denmark. Since these 
findings may not be representative for other countries, we aimed to compare different 
countries in Chapter 7. This chapter studies the international usage of 
benzodiazepines before, during and after pregnancy in a meta-analysis. 
In Chapter 8, we present a general discussion of the main conclusions, 
methodological consideration, clinical implications and implications for future 
research. Finally, we give a final conclusion of this thesis. 
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Abstract 
Background: Depression during pregnancy is a common and high impact disease. 
Generally, 5-10% of pregnant women suffer from depression. Children who have 
been exposed to maternal depression during pregnancy have a higher risk of 
adverse birth outcomes and more often show cognitive, emotional and behavioural 
problems. Therefore, early detection and treatment of antepartum depression is 
necessary. Both psychotherapy and antidepressant medication, first choice 
treatments in a non-pregnant population, have limitations in treating depression 
during pregnancy. Therefore, it is urgent and relevant to investigate alternative 
treatments for antepartum depression. Bright light therapy (BLT) is a promising 
treatment for pregnant women with depressive disorder, for it combines direct 
availability, sufficient efficacy, low costs and high safety, taking the safety for the 
unborn child into account as well.  
Methods: In this study, 150 pregnant women (12-18 weeks pregnant) with a DSM-
V diagnosis of depressive disorder will be randomly allocated in a 1:1 ratio to one 
of the two treatment arms: treatment with BLT (9.000 lux) or treatment with dim red 
light therapy (100 lux). Both groups will be treated for 6 weeks at home on a daily 
basis for 30 minutes, within 30 minutes of habitual wake-up time. Follow-up will 
take place after 6 weeks of therapy, 3 and 10 weeks after end of therapy, at birth 
and 2, 6 and 18 months postpartum. Primary outcome will be the average change 
in depressive symptoms between the two groups, as measured by the Structured 
Interview Guide for the Hamilton Depression Scale – Seasonal Affective Disorder 
version and the Edinburg Postnatal Depression Scale. Changes in rating scale 
scores of these questionnaires over time will be analysed using generalized linear 
mixed models. Secondary outcomes will be the changes in maternal cortisol and 
melatonin levels, in maternal sleep quality and gestational age, birth weight, infant 
behaviour, infant cortisol exposure and infant cortisol stress response. 
Discussion: If BLT reduces depressive symptoms in pregnant women, it will 
provide a safe, cheap, non-pharmacological and efficacious alternative treatment 
for psychotherapy and antidepressant medication in treating antepartum 
depression, without any expected adverse reactions for the unborn child.  
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Background 
Depression during pregnancy is a common and high impact disease. 
Approximately 5-10% of pregnant women suffers from depression [1], which has 
been confirmed by a study in Rotterdam, the second largest city in the Netherlands 
[2]. Children who are exposed to maternal depression during pregnancy have a 
higher risk of adverse birth outcomes, such as low birth weight, and more often 
show cognitive, emotional and behavioural problems [3-6]. The perinatal period is a 
critical period, in which epigenetic programming determines not only the perinatal 
health, but also that of following generations [7]. Therefore, early detection and 
prompt treatment of depression during pregnancy can benefit both mother and 
child.  
In non-pregnant women, guidelines propose psychotherapy, antidepressant 
medication or a combination of both as treatment for depression. However, clinical 
practice shows limited relevance of these guidelines during pregnancy, as the 
direct availability of psychotherapists is poor, postponing treatment for several 
months or more. In pregnancy, the window of opportunity is small and from the 
perspective of the child postponement is in fact non-treatment. Other limitations of 
psychotherapy are its dependence on good language skills, absence of problems 
that limit access to therapy and a strong motivation to reflect on ones emotions, 
cognition and behaviour. These factors limit the applicability of psychotherapy in a 
majority of pregnant women with depression, who share a socioeconomic deprived 
background and often have coexisting problems interfering with compliance [8]. 
Therefore, women with depression during pregnancy may be treated with 
antidepressants. In North America, use of antidepressants during pregnancy is 
reported by 5-13% of pregnant women [9, 10]. In the Netherlands, 2-3% of 
pregnant women use antidepressant medication [11, 12]. However, the safety of 
these medications during pregnancy is controversial [13, 14]. 
Therefore, investigating non-pharmacological approaches to treating depression 
during pregnancy is urgent and relevant, for both mother and child. Bright light 
therapy (BLT) is a promising treatment for pregnant women with depression based 
on several theoretical and clinical considerations, which will be discussed below. 
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BLT and depression 
BLT is the first choice treatment for seasonal affective disorder (SAD) [15], a 
condition of reoccurring depressions during fall and winter, with remissions in 
spring and summer [16]. 
The effects of BLT have not only been consistently shown on SAD [16-19], but also 
on other diseases, such as non-seasonal depression [17],  adult attention-
deficit/hyperactivity disorder [20] and bulimia nervosa [21, 22]. The effects of BLT 
on non-seasonal depression have been shown in various populations, like elderly 
residents of group care facilities and patients with Alzheimer’s disease [23-25].  
BLT has been shown to synchronize the biological clock with the environmental 
day-night rhythm and to shift the circadian rhythm [15, 16]. Evidence suggests that 
this mediates the effects of BLT on depression, which has been indirectly 
supported by enhanced sleep and rhythms of melatonin and cortisol [23]. 
 
Hypothalamus-pituitary-adrenal axis 
The hypothalamus-pituitary-adrenal gland (HPA) axis is involved in the 
synchronization of the biological clock by BLT. This axis regulates the secretion of 
cortisol in response to stress [26]. HPA-axis activity is controlled by the 
corticotropin-releasing factor (CRF) secreted by parvocellular neurosecretory cells 
in the paraventricular nucleus (PVN) of the hypothalamus, which activates the 
secretion of adrenocorticotrophic hormone (ACTH) from the anterior pituitary, 
which in turn stimulates the production and release of cortisol from the adrenal 
cortex [26, 27]. CRF and ACTH are both inhibited by cortisol through the 
glucocorticoid receptor (GR) [26, 27]. Figure 2.1 shows a schematic overview of 
this feedback loop. 
The cause of depression is largely unknown. However, the HPA-axis is thought to 
play a crucial role in the pathophysiology – as cause or consequence, since 
hyperactivity of this axis is associated with depression. More specifically, 
depression is thought to be related to reduced inhibition by cortisol, due to impaired 
GR function [27]. This is supported by a post-mortem study among depressed 
patients, which showed hyperactivity of CRF neurons of the hypothalamic PVN 
[28]. Second, increased basal cortisol levels are commonly found in patients with 
depression [27]. 
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Figure 2.1 – Schematic diagram of the hypothalamus-pituitary-adrenal gland (HPA) 
axis.  
Shown are the different structures and hormones involved in the HPA-axis. CRF, 
produced and released by the hypothalamus, stimulates the anterior pituitary to 
produce and release ACTH, which in turn stimulates the production and release of 
cortisol by the adrenal cortex. Cortisol inhibits both the hypothalamus and pituitary 
through the GR. 
PVN = paraventricular nucleus; GR = glucocorticoid receptor; CRF = adrenocorticotrophic hormone 
releasing factor; ACTH = adrenocorticotrophic hormone; + = stimulating; - = inhibiting. 
 
Suprachiasmatic nucleus  
The suprachiasmatic nucleus (SCN), known as the ‘biological clock’, controls the 
HPA-axis: decreased inhibitory control of the SCN on the HPA-axis has been 
shown to be associated with HPA-axis hyperactivity [29]. The SCN is located in the 
hypothalamus on top of the optic chiasm and is the central pacemaker of all 
physiological and behavioural rhythms [15, 30]. Light is the most powerful 
environmental signal that synchronizes the SCN with the environmental day-night 
rhythm (also known as ‘zeitgeber’). Environmental light versus darkness is 
signalled to the SCN by melanopsin-containing retinal ganglion cells through the 
retino-hypothalamic tract in the optic nerve (Figure 2.2) [15, 31]. The SCN is able to 
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maintain circadian rhythms, even in the absence of zeitgebers [15, 30]. This central 
control function of circadian rhythms is lost when the SCN is damaged or 
obliterated. Mice studies have shown that ablation of the SCN results in 
arrhythmicity [32, 33]. A case report of a patient with hypothalamic damage 
demonstrated disturbances in the sleep-wake cycle, body temperature and 
cognitive and behavioural functioning [34]. 
 
 
 
 
Figure 2.2 – Sagittal view of the brain.  
This figure shows a sagittal view of the suprachiasmatic nucleus, the optic chiasm, the 
optic nerve, the hypothalamus, the pituitary and the pineal gland. 
 
Melatonin 
Melatonin is, next to cortisol, influenced by light. Melatonin is produced and 
secreted by the pineal gland and, like other circadian rhythms, its rhythm is 
controlled by the SCN (Figure 2.2) [35, 36]. Typically, melatonin levels rise in the 
evening, peak at early morning hours and drop to baseline at awakening [26]. Light 
inhibits the production of melatonin [26]. 
Different studies showed a change in melatonin secretion in psychiatric diseases, 
such as a reduction of melatonin secretion in depression [35, 37]. Earlier, BLT in 
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the morning has been shown to normalize saliva melatonin evening levels in 
elderly patients with a depressive disorder [23].  
Melatonin concentrations increase during the course of pregnancy [36]. However, a 
study showed that nocturnal melatonin levels were lower in depressed pregnant 
women, compared to healthy controls [38]. In this study, we want to explore the 
effects of BLT on evening and morning melatonin levels. 
 
BLT and depression during pregnancy 
The SCN generates the circadian rhythms in physiology and behaviour, including 
reproductive hormones. Pregnant women typically show disturbed, desynchronised 
circadian rhythms, resulting in disturbed sleep patterns, which puts them at risk for 
depression [39]. Moreover, disturbed sleep and decreased physical condition put 
pregnant women at risk for decreased activity and less exposure to daylight [40], 
which might further enhance their risk for depression. 
Two small (n=10 and n=27) randomized controlled trials among pregnant women 
with non-seasonal depression showed significant improvement of depression 
among women exposed to BLT compared to placebo [41, 42]. Treatment effect in 
terms of mean improvement of depressive symptoms was comparable with the 
effects of antidepressant medication (effect size around 0.45), making it a 
competitive treatment for antepartum depression, but without the possible adverse 
effects of medication to the unborn child. Although these studies provide evidence 
for the effectiveness of BLT for depression during pregnancy, their sample size is 
small.  
While in previous studies among elderly patients cortisol and melatonin rhythms 
normalized after BLT treatment [23], the question is whether improvement of 
depressive symptoms after BLT in pregnant women is also mediated through 
improved endocrine functioning or whether these symptoms are primarily 
determined by the physiology of pregnancy itself. Therefore, we will also examine 
the circadian rhythms and hormone levels of the pregnant women, to study 
whether BLT also effects endocrine functioning during pregnancy. 
From previous research, we know that maternal depression during pregnancy 
negatively influences intra-uterine and postnatal child development [3-6, 43-47]. 
How intra-uterine child development is influenced by maternal depression has yet 
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to be determined. Possible mechanisms are maternal cortisol crossing the 
placenta, placental secretion of CRH – which has a positive feedback loop with 
maternal and foetal cortisol – and reduced blood flow to the foetus, causing foetal 
growth restriction [5, 43-45, 47]. Increased maternal levels of cortisol, as a cause 
and/or consequence of maternal depression during pregnancy, might program the 
intra-uterine developing HPA-axis of the child, making it susceptible to increased 
stress reactivity in future life [3, 4, 48], which has also been confirmed in animal 
studies [49]. Therefore, where the earlier conducted studies on antepartum 
depression and BLT only studied the effects of BLT on mood [41, 42], it will be 
interesting to examine the effects on infant stress reactivity, long-term cortisol 
exposure and infant behaviour. 
 
Aims 
In this study, we will primarily study the effects of BLT on depression during 
pregnancy, including adverse effects. Second, we will study whether this clinical 
improvement is accompanied by improved sleep quality and normalized melatonin 
and cortisol levels during pregnancy. Third, we will study the effects of BLT on 
gestational age, birth weight, infant behaviour, infant cortisol stress response and 
long-term cortisol exposure of the infant. 
 
Methods/Design 
Hypotheses 
Primary hypothesis: Daily treatment with 6 weeks of morning BLT improves 
depressive symptoms during pregnancy. 
Secondary hypotheses: 
1. Clinical improvement of depressive symptoms is accompanied by 
improved sleep patterns, lower basal cortisol levels and normalized 
melatonin concentrations during pregnancy.  
2. Treatment with BLT during pregnancy improves birth and child outcomes: 
higher gestational age, higher birth weight, less regulation problems in 
infants and lower cortisol stress response. In addition, infants will show 
lower long-term cortisol exposure. 
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Figure 2.3 – Flowchart of overview study. 
DSM = Diagnostic and Statistical Manual of Mental Disorders; BLT = bright light therapy; DRLT = dim red 
light therapy. 
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Study overview 
This study is a randomized, double-blind, placebo-controlled clinical trial. After 
baseline measurements (T0), the participants will be randomly allocated to either 
receive active BLT or dim red light therapy (DRLT) in a 1:1 ratio. Subsequently, 
they will commence their daily treatment with light, which takes place at the 
participants’ home for 6 weeks. After treatment, follow-up will take place at the 
following time points:  
 after 6 weeks of treatment, which marks the end of treatment (T1); 
 3 weeks after end of treatment (T2); 
 10 weeks after end of treatment (T3); 
 at birth (T4); 
 2 months postpartum (T5); 
 6 months postpartum (T6); 
 18 months postpartum (T7). 
At these time points, questionnaires, body material and information from medical 
files will be collected (Table 2.1). A flowchart of this study is shown in Figure 2.3. 
 
Participants 
In this study, pregnant women with a depressive disorder will be eligible for 
participation. The specific inclusion and exclusion criteria of the study are listed in 
Table 2.2. 
 
Recruitment 
In the Netherlands, maternity care for low-risk pregnancies is provided in primary 
care, which is midwife-led. High-risk pregnancies are cared for in a general hospital 
(secondary care) or foetal-maternal medicine unit (tertiary care). 
In this study, women will be mainly recruited through both midwifery practices and 
hospitals participating in the South West Consortium in the Netherlands. This is a 
unique consortium in which almost all parties involved in perinatal care in the South 
West region of the Netherlands are united: midwives, obstetricians, paediatrician, 
and several public health institutes. The consortium covers both urban areas (such 
as the city Rotterdam) and rural areas. Previous studies in this consortium involved 
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screening for psychosocial risk factors, psychiatric disease and the impact of 
structuring psychosocial care. Rotterdam is the second largest city in the 
Netherlands with more than 620.000 inhabitants [50]. It has a high number of 
deprived neighbourhoods, defined as 10% of pregnant women having a low socio-
economic status (<20th percentile) [51]. 
 
Table 2.1 – Overview assessment of questionnaires and collection of body material 
and medical files per time point. 
 T0 IP a T1 T2 T3 T4 T5 T6 T7 
Questionnaires          
SIGH-SAD X X X X  X   X X X 
EPDS X X X X  X   X X X 
Life events X X X X X  X X X 
PSQI X X X X X  X   
User expectations X         
User experiences   X     X    
MABS       X    
CBCL         X 
          
Body material          
Urine cortisol X   X  X    X   
Saliva 
cortisol/melatonin 
X   X  X    X   
Hair cortisol X    X   X   
Saliva cortisol 
(infant) 
      X    
Hair cortisol (infant)       X   
          
Actigraphy X b     X c   X c   
          
Collecting medical 
files 
     X    
a In the intervention period, the questionnaires will be assessed weekly. 
b The actiwatch needs to be worn for 8 weeks at T0. 
c At T3 and T5, the actiwatch needs to be worn for 9 days. 
T0 = baseline (start of treatment); T1 = after 6 weeks of treatment (end of treatment); T2 = 3 weeks after 
treatment; T3 = 10 weeks after treatment; T4 = birth; T5 = 2 months postpartum. 
IP = intervention period; SIGH-SAD = Structured Interview Guide for the Hamilton Depression Scale – 
Seasonal Affective Disorder version; EPDS = Edinburgh Postnatal Depression Scale; PSQI = Pittsburgh 
Sleep Quality Index; MABS = Mother and Baby Scales; CBCL = Child Behaviour Checklist. 
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Table 2.2 – Inclusion and exclusion criteria. 
Inclusion criteria Women 
 18-45 years of age 
 12-18 weeks pregnant 
 DSM-V diagnosis of depressive disorder (as assessed by the 
Structured Clinical Interview for DSM disorders) 
  
Exclusion criteria Insufficient proficiency in Dutch or English 
 Multiple pregnancy 
 The use of antidepressants shorter than 2 months 
 Bipolar I or II disorder 
 Any psychotic episode 
 Substance abuse 
 Primary anxiety disorder 
 Recent history of suicide attempt 
 Shift-work 
 Somatic and/or obstetric conditions that override study 
participation 
 Previous treatment with BLT 
 Eye condition (macular degeneration, eye diseases, recent 
eye surgery) 
 
Women will be routinely screened on psychopathology and psychosocial problems 
during their first prenatal visit in midwifery practices and hospitals by a screening 
model, the Mind2Care [2]. During this screening, women are asked to fill out a 
web-based questionnaire, consisting of 33 items, covering four domains: a socio-
demographic, obstetric, psychiatric and psychosocial domain, including the 
Edinburgh Postnatal Depression Scale (EPDS) [52]. A cut-off score of 9 or above 
of the EPDS is used by the Mind2Care, in order to refer a woman towards tailored 
mental health care. Sensitivity and specificity of the EPDS are respectively 86% 
and 78% [52]. 
In addition, women who visit our outpatient psychiatric clinic – a centre of 
excellence in perinatal psychiatry – at the Erasmus University Medical Centre in 
Rotterdam for their depressive symptoms will be offered to participate in our study 
when they are not fully remitted from depressive symptoms after 2 months of 
treatment with antidepressant medication and/or other psychiatric treatment. 
Third, pregnant women who visit their general practitioner (GP) for depressive 
symptoms may be referred to the study by their GP.  
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Finally, women will be recruited via (social) media, such as press releases, so 
women with depressive symptoms can enrol in the study without referral from their 
midwife, gynaecologist, GP or mental health care worker.  
 
Ethics 
This study will be conducted in accordance with the Helsinki Declaration, meaning 
that participation is voluntary and written informed consent will be obtained. Before 
entering the study, subjects will receive information about the study and its risks 
and benefits, verbal and in writing. Subjects will have a reflection period of one 
week. Participants can leave the study at any time for any reason without 
consequences with regard to their current or future treatment. Also, the investigator 
can decide to withdraw a participant from the study for urgent medical reasons. 
The study has been approved by the medical ethical committee of the Erasmus 
University Medical Centre, Rotterdam, The Netherlands (registration number MEC-
2015-731). A Data Safety Monitoring Board has been installed, which monitors the 
safety of this research.  
In case of adverse effects, a treatment protocol will be effective. 
 
Randomization and blinding 
We will randomly assign 150 participants in a 1:1 allocation ratio to either receive 
BLT or DRLT. Randomization will be done with the web-based computer-generated 
randomization schedule ALEA (software for randomization in clinical trials, version 
2.2) using random block sizes of 2 to 6. Stratification factors will be the use of any 
antidepressant medication and the number of previous depressive episodes. This 
will be dichotomized to 3 or less previous depressive episodes versus 4 or more 
[53]. 
Participants will be blinded for their allocation. They will be informed that this study 
examines the efficacy of light therapy with two different colours.  
Participants will be asked to guess to which treatment group they are allocated to 
after treatment, as suggested by the Cochrane’s Collaboration’s tool for assessing 
risk of bias in randomized trials [54]. 
Blinded, independent assessors will be involved in the outcome ratings and will 
conduct the interviews at T1, T2, T3, T5, T6 and T7 and on a weekly base during 
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the intervention period. The participants are asked not to share any details about 
their treatment towards the assessors. In case information is shared, the assessor 
will be replaced. After each interview, the assessors will be asked to guess the 
allocation of the participant.  
The researcher who will perform the primary statistical analysis (AK) will be blinded 
for allocation. 
The field researcher (BB) will install the lamps and will provide the participants with 
instructions. Also, the field researcher will answer any questions asked by 
participants. For this, we will use protocolled answers, to maintain the blindness of 
the participants. Moreover, the field researcher will ask the participants about side-
effects at T1 and on a weekly base during the intervention, keeping the 
independent assessors blinded for adverse effects that might break the blinding, 
e.g. strained eyes. For these practical reasons, the field researcher will not be 
blinded.  
 
Intervention 
Participants will be randomly allocated to BLT (9.000 lux) or DRLT (100 lux). 
Treatment will take place daily at home for 6 weeks, starting at 12-18 weeks 
pregnancy. Participants will be asked to commence the treatment within 30 
minutes of habitual wake-up time with a duration of 30 minutes. Participants will sit 
in front of two light boxes with a distance of approximately 40 cm. The light boxes 
will be placed in a custom-made scaffolding. In this way, the height of the light 
boxes can be adjusted per person, ensuring the same distance. Also, the 
scaffolding ensures lighting from above, which avoids glare [42]. This makes the 
treatment more comfortable, enhancing treatment adherence. 
The active dose was found effective in other studies [23, 41, 42]. Dim red light can 
be considered to be biologically inactive [55]. Although a Cochrane review of 
studies in BLT in non-seasonal depression showed that BLT may be effective in as 
little as 1 week [55], we will choose 6 weeks of daily light exposure, since the 2 
studies among pregnant women with non-seasonal depression showed significant 
effects of BLT from 5 weeks treatment [41, 42]. 
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All participants in both treatment arms will receive treatment as usual. Women are 
always free to visit their GP, whenever they are in need of this. The GP is always 
free to start treatment if he/she feels necessary. 
When depressive symptoms increase and/or in the case of suicidal ideation, an 
action plan is set up and appropriate measures will be taken. 
Different measures have been taken to enhance treatment adherence: 
 A sensor that measures the amount of lux perceived is installed in the 
actiwatches, which will monitor the therapy adherence.  
 Since the lamps will be installed into a custom-made scaffolding that 
ensures lighting from above, treatment will be more comfortable, which 
enhances treatment adherence. 
 
Outcome measures 
The primary outcome measure will be the average change in depressive symptoms 
between the two groups, as measured by the Structured Interview Guide for the 
Hamilton Depression Scale – Seasonal Affective Disorder version (SIGH-SAD) and 
the EPDS at different time points. Second, we will study responders vs. non-
responders, where response is defined as a ≥50% decrease to a final score of ≤ 8 
on the 17-item Hamilton scale and ≤ 5 on the EPDS. 
The secondary outcome measures of this study will be the changes in maternal 
cortisol and melatonin levels (1), in maternal circadian rhythm (2) and in birth and 
child outcomes (3).  
1. Morning and evening cortisol levels in saliva will be measured as a 
measure for HPA-axis activity. Morning and evening melatonin levels in 
saliva will be measured as measure of a participant’s circadian phase 
position. Outcome measures will be the changes in cortisol and melatonin 
saliva levels between the two groups. 
Total 24-hour cortisol excretion will be determined from urine. Outcome 
measure will be the changes in cortisol levels within and between the two 
groups. 
Hair will be used as a long-term measure for cortisol excretion. Changes in 
levels between the two groups will be used as outcome measure. 
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2. Through actiwatches and a structured questionnaire (the Pittsburgh Sleep 
Quality Index – PSQI), information will be obtained regarding total sleep 
time, sleep efficiency and sleep onset latency, as well as circadian 
estimates from the rest activity rhythm such as intradaily and interdaily 
variability and rhythm amplitude.   
3. Differences in birth and child outcomes between the two groups will be 
used as outcome measures: pregnancy duration, birth weight, child 
behaviour, long-term cortisol exposure and cortisol stress response at a 
routine vaccination. 
Finally, we will ask about user expectations and user experiences. 
Complete follow-up will be pursued. In case of discontinuing or deviating from the 
intervention, we will collect outcomes of EPDS and SIGH-SAD assessment. 
 
Sample size 
Based on previous literature [23, 41, 56], we expect a small to moderate response 
(time x treatment interaction on depressive symptoms). This corresponds to a 10 to 
15% reduction of depressive symptoms over the full course of treatment. To 
demonstrate this (with an α of 0.05 and a β of 0.80), we will need a sample size of 
63 participants per arm (126 in total). To account for lost to follow up during and 
after treatment, we will aim at including 150 participants. Power calculations were 
performed using GLIMMPSE 2.1.5 software [57]. 
In case of withdrawal of a participant during the recruitment period, another 
participant will be recruited to obtain the aimed number of participants.  
 
Adverse effects  
At every measurement, we will ask for adverse effects. The adverse effects of BLT, 
such as headache and nausea, are generally mild and short-lived [58, 59]. A switch 
to hypomania is a more serious adverse effect, which would require effect 
managing. In a study exploring the side effects of short-term 10,000 lux light 
therapy in 70 patients suffering from SAD, 1 subject experienced hypomania [58]. 
In the two studies (n=10 and n=27) studying the effects of light therapy in a 
pregnant population, 1 subject showed hypomanic symptoms [41, 42]. If a 
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participant shows hypomanic symptoms, the daily treatment duration will be 
reduced. This enhances the clinical safety [41].  
No adverse effects for the foetus will be expected [42, 56]. 
 
Inclusion 
Women will be asked to provide the following baseline socio-demographic factors: 
age, ethnicity, level of education, marital status, parity, unplanned pregnancy, body 
mass index, somatic conditions (if not exclusion), medication use and substance 
use (smoking, alcohol, drugs).  
The GP will be contacted to verify whether the participant meets any exclusion 
criteria. The results will be discussed with an experienced perinatal psychiatrist 
(ML), who will – as a safety measure – verify the diagnosis and inclusion and 
exclusion criteria. If there are no clinical contraindications, randomization will take 
place. 
After a positive screening on the EPDS, eligible women will be interviewed to 
assess lifetime psychiatric diagnosis. This will be done with the Structured Clinical 
Interview for DSM disorders (SCID), a semi-structured interview that is considered 
to be the golden standard for making the major DSM-V axis I psychiatric diagnoses 
[60]. 
 
Measurements – primary outcome measures 
Depressive symptoms during pregnancy will be assessed using the SIGH-SAD and 
the EPDS. 
 
 SIGH-SAD 
The SIGH-SAD is a 29-item structured interview and consists of 21 HAM-D 
(Hamilton Rating Scale for Depression) items and 8 atypical items, of which 11 
items can be scored with a value of 0-2, 5 items with a value of 0-3 and 13 items 
with a value of 0-4 [61]. The sum score ranges from 0 to 63 for the HAM-D items 
and from 0 to 26 for the atypical items, resulting in a total sum score of 0 to 89 [61].  
We will choose the original 17-item HAM-D questionnaire as primary measure, 
since it is more commonly used in clinical practice and research. Interrater 
reliability for the 17-item HAM-D questionnaire ranges from 0.82 to 0.98 [62]. 
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Sensitivity and specificity are respectively 0.76 and 0.91 [62]. Positive and negative 
predictive value are respectively 0.77 and 0.92 [62]. Next to the original 17-item 
HAM-D questionnaire, we will use the entire SIGH-SAD questionnaire, since this 
questionnaire is the current benchmark for assessment of severity of depression in 
light therapy trials. 
 
 EPDS 
The EPDS, a structured 10-item questionnaire, will be used as a validated self-
report measure of depression during pregnancy [52, 63]. Each item is scored with a 
value, ranging from 0 to 3, which leads to a sum score of 0 to 30 [52]. Sensitivity 
and specificity of the EPDS are respectively 86% and 78% [52]. Originally, the 
EPDS was developed for the detection of postnatal depression, but has been 
validated for screening depression during pregnancy as well [63]. In this study, we 
will use a cut-off of 9, in accordance with the screening tool, the Mind2Care [2]. 
 
Measurements – secondary outcomes (endocrine) 
Endocrine levels during pregnancy will be studied measuring saliva melatonin and 
cortisol in urine, saliva and hair. 
 
 Urinary free cortisol 
Urinary free cortisol levels during a 24-hour period provide a non-invasive valid 
estimation of overall daily cortisol production [64]. Urine will be collected starting 
after the first voided urine after awakening and will include the first voided urine on 
the following day. The cortisol level will be determined by radioimmunoassay. 
Completeness of collection will be ascertained by interviews documenting urine 
losses. Only complete collections, with creatinine within the normal range of 0.06 
mg/dL per 24 hours will be included in the analysis.  
 
 Saliva cortisol 
As a measure of HPA-axis activity, saliva cortisol will be collected using cotton 
dental rolls, including 4 sequential samples at 30-minutes intervals starting at 
awakening and 3 sequential samples at hourly intervals starting 2 hours before 
predicted bedtime with the last sample at bedtime. The samples will be collected 
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the following day and subsequently delivered to the laboratory, where they will be 
centrifuged and stored at -80°C. Samples will be analysed using a cortisol assay 
on an immunoanalyser system. For determination of the diurnal time course of 
saliva cortisol levels, only days with at least 6 valid samples will be included in 
analyses.  
 
 Hair cortisol 
Hair cortisol will be assessed as a validated biomarker for long-term cortisol 
exposure. The maternal hair strands will be collected and processed according to 
existing methods [65]. With this method, cortisol levels can be retrospectively 
assessed depending on hair length (i.e. one month for each centimetre of hair). 
Norm data from healthy pregnant controls will be available through one of our other 
ongoing studies.  
 
 Saliva melatonin 
As a measure of a participant’s circadian phase position, saliva melatonin levels 
will be collected using cotton dental rolls at hourly intervals with 3 sequential 
samples, starting 2 hours before predicted bedtime with the last sample at bedtime, 
under dim light conditions. One sample will be taken at awakening. The samples 
will be collected the following day and subsequently delivered to the laboratory, 
where they will be centrifuged and stored at -80°C. All samples will be analysed 
using Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS). For 
determination of a rise in melatonin levels in het evening, only days with 3 valid 
evening samples will be included in the analyses [23]. 
The Dim Light Melatonin Onset (DLMO; the time point when melatonin secretion 
rises over a predefined threshold in the evening [66]) will be calculated after 
measuring the melatonin evening curve. The DLMO is a reliable estimate of 
circadian phase position [66]. 
 
Measurements – secondary outcome measures (circadian rhythm) 
The circadian rhythm during pregnancy will be studied through actiwatches and the 
PSQI.  
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 Actigraphy 
Actigraphy, the continuous assessment of activity with a watch-sized non-dominant 
wrist-worn recorder (Actiwatch Spectrum, Philips Respironics, Pittsburgh, USA), is 
a validated technique to obtain estimates of sleep and rest-activity rhythms [23, 67, 
68]. Sleep analyses software (Actiware 6.0, Philips Respironics, Pittsburgh, USA) 
will be used to obtain estimates of sleep parameters. The software will calculate 
end and start of sleep. Further, assumed sleep (the difference between the end 
and the start of sleep), actual sleep time (amount of sleep determined by 
algorithm), sleep onset latency (the time between lights out and sleep onset) and 
sleep efficiency (the percentage of actual sleep time between sleep onset and final 
awakening, excluding sleep onset latency) will be calculated [23]. Rest-activity 
rhythms will be calculated, using different actimetric variables, such as interdaily 
stability and intradaily variability [23]. 
 
 PSQI 
The PSQI, a structured 19-item self-questionnaire with 5 additional items reported 
by bedpartner, assesses sleep quality, including a wide variety of factors, such as 
sleep duration and latency [69]. The sum score ranges from 0 to 21 points, with 
higher values corresponding to lower sleep quality [69]. These 19 items generate 7 
component scores: subjective sleep quality, sleep latency, sleep duration, habitual 
sleep efficiency, sleep disturbances, use of sleeping medication and daytime 
dysfunction [69]. 
A cut-off of 5 will be applied, where a score of <5 indicates poor sleep and ≥5 
indicates good sleep [69]. The PSQI has a sensitivity of 89.6% and a specificity of 
86.5% [69]. 
The PSQI will be assessed on a monthly base and weekly in the intervention 
period. 
 
Measurements – secondary outcome measures (infant) 
As infant outcome measures, birth outcomes, infant stress response, infant long-
term cortisol exposure and behaviour will be studied.  
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Birth outcomes 
After birth (T4), information will be obtained regarding complications during delivery 
and childbirth from the medical records: hypertension, pre-eclampsia, delivery 
aspects (duration, start with or without induction, augmentation, method of pain 
relief if any, instrumental delivery, caesarean section, hospital admission) and first 
week complications after delivery.  
 
 Infant stress response 
To measure the infant stress response, we will collect saliva cortisol before and 15, 
30 and 45 minutes after a routine vaccination at T5. We will use the same 
procedures and analyses as with the mothers. 
 
 Infant long-term cortisol exposure 
To measure the long-term cortisol (intra-uterine) exposure, we will collect hair 
samples of the infant at T5. We will use the same procedures and analyses as with 
the mothers.  
 
 Infant behaviour 
To study infant behaviour, we will assess the questionnaires Mother and Baby 
Scales (MABS) and Child Behaviour Checklist (CBCL). 
 
  MABS 
We ask mothers (and fathers, if available) to fill out the MABS, a questionnaire 
consisting of various subscales [70]. In this study, we use 3 subscales of the 
MABS: infant alertness-responsiveness, unsettled-irregular behaviour of the infant 
and lack of confidence in care-taking [70], resulting in a 36-item questionnaire.  
The unsettled-irregular behaviour scale consists of 8 items (e.g. ‘After feeds, I’ve 
used rocking or cuddling to settle my baby), the alertness-responsiveness scale of 
15 items (e.g. ‘My baby watches my face’) and the lack of confidence in feeding of 
13 items (e.g. ‘I’ve felt clumsy in caring for my baby’). Parents are asked to score 
the various statements with a score between 0 (not at all) and 5 (very much/often), 
which results in a sum score of 0-180. The subscale sum scores range from 0 to 75 
for infant unsettled-irregular behaviour, from 0 to 40 for infant alertness-
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responsiveness and from 0 to 65 for lack of confidence in care-taking [70]. A higher 
score on the infant unsettled-irregular behaviour scale correlates to more irregular 
behaviour, whereas a higher score on the infant alertness-responsiveness scale 
points to more alert behaviour [71]. A higher score on the lack of confidence scale 
suggests that the mother is less confident in taking care of the baby. Reliability of 
the MABS ranges from 0.81 to 0.93 (Cronbach’s α), depending on the used 
subscale [70]. 
 
  CBCL 
We ask mothers (and fathers, if available) to fill out the CBCL/1.5-5, a diagnostic 
99-item questionnaire which quantifies skills and behavioural problems. The 
questionnaire consists of different scales: emotionally reactive, anxious/depressed, 
somatic complaints, withdrawn, sleep problems (Internalizing Problems), attention 
problems and aggressive behaviour (Externalizing Problems) [72]. Together, the 
Externalizing and Internalizing Problems form the Total Problems [72]. Items can 
be scored with 0 (not at all), 1 (a little or sometimes) or 2 (clearly or often), resulting 
in different sum scores for the different scales. Norms for these scales were 
constructed, using a large representative sample of children [72]. 
Reliability of the CBCL is 0.85 [73]. 
 
Chronotype 
The participant’s chronotype will be verified at screening, since evening types are 
found to be more prone to depression than morning types [74, 75]. In this study, 
this will be assessed with the Munich Chronotype Questionnaire (MCTQ), a 
structured 19-item self-report measure of an individual’s chronotype, based on 
sleep times, self-reported light exposure and self-assessed chronotype (extreme, 
moderate or slight early, normal or slight, moderate or extreme late), taking rest 
and working days in consideration [76]. The participant can be classified to 1 of the 
7 chronotypes by utilizing data on the participant’s midsleep phase and sleep debt 
[76]. Sum score ranges from 16 to 86, with the lowest score indicating extreme late 
chronotypes. The MCTQ correlates well with the Horne-Östberg Morningness-
Eveningness Questionnaire – especially the MCTQ-assessment of time of 
midsleep (r=-0.73 on free days and r=-0.61 on workdays) [77].  
Chapter 2 
52 
 
Statistical analysis – general  
Data will be analysed using SPSS 21.0. For treatment effect analyses, we will 
apply an intention-to-treat procedure, since none of the participants will switch to 
another condition and we will include all observations of all participants until study 
end or withdrawal.  
If necessary, skewed continuous variables will be transformed to normality prior to 
the analyses.  
For the continuous variables and categorical variables that are assessed more than 
twice, we will deploy linear mixed models and generalized linear mixed models 
respectively. These models use all available data and account for within-subject 
correlation over time. They can also be used to adequately deal with possible 
baseline imbalances. Variables measured only once will be compared between the 
randomized groups using the unpaired t-test, or the Chi-Square test in case of 
categorical variables. All effect parameters will be supplied with a 95% confidence 
interval.  
Primary outcome analysis will be first crude, than adjusted. If despite 
randomization, prognostically important factors differ between the groups, they will 
be adjusted for supplemental analyses. 
 
Statistical analysis – primary outcomes 
Changes in HAM-D and EPDS rating scale scores over time will be analysed using 
generalized linear mixed models. Differences from baseline of HAM-D and EPDS 
scores at every time point will be the dependent variables, time will be the within-
subject factor and treatment (BLT versus DRLT) will be the between-subjects 
factor.  
Additional analysis will use alternative definitions of change: instead of the 
numerical difference of scores before and after, we will use a dichotomous 
response variable where improvement of ≥ 50% to a final score ≤ 8 on HAM-D and 
≤ 5 on EPDS is defined as success, otherwise not. Finally, we will perform 
sensitivity analysis to examine robustness of the findings with other methods using 
data imputation (last observation carried forward multiple imputation). 
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Statistical analysis – secondary outcomes 
For saliva cortisol, areas under the curves for the morning and evening (i.e. 7 to 9 
AM and 8 to 11 PM) will be calculated for subsequent analyses [23]. For saliva 
melatonin, areas under the curves for the evening (i.e. 8 to 11 PM) will be 
calculated for subsequent analyses [23]. 
Continuous outcomes, e.g. saliva cortisol and melatonin, will be tested with the 
unpaired t-test and linear mixed model. Categorical outcomes, e.g. sleep quality, 
will be tested with Chi-Square Test and generalized linear mixed model. 
 
Statistical analysis – covariates  
Potential covariates for the mother are psychiatric history, ethnicity, level of 
education, parity, gestational age (duration of pregnancy at study entry), substance 
use, chronotypes, duration of actual depression and other psychiatric or 
psychotherapeutic treatment interventions. These factors might affect depressive 
symptoms during pregnancy. After pregnancy, we will additionally correct for 
complications during delivery, breastfeeding and objective and subjective sleep 
parameters, since these factors might influence depressive symptoms after 
delivery.  
Potential covariates for the infant are head circumference, congenital 
malformations, Apgar-score and neonatal admission at Neonatal Intensive Care 
Unit. 
 
Discussion 
We have presented a protocol for an RCT of light therapy for antepartum 
depression. Two earlier conducted RCT’s have shown the effects of BLT in 
pregnant women with depression, but studied only a small sample size (n=10 and 
n=27) [41, 42]. In this trial, we will study the effects of BLT on antepartum 
depression in a larger sample (n=150) and in addition to the earlier conducted 
studies, we will not only study the effects of BLT on the mother, but on the infant as 
well. Moreover, we will study the effects of BLT on maternal endocrine levels and 
maternal circadian rhythm. 
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BLT will benefit pregnant women, for they will receive immediate treatment for their 
depressive symptoms. Psychotherapists are not always available, which would 
postpone treatment. Also, antidepressant medication is not immediately effective. 
However, BLT may be effective in as little as 1 week [55]. Moreover, the adverse 
effects of BLT are mild and short-lived. 
The unborn child would benefit from this alternative treatment, for BLT does not 
cause adverse effects in the unborn child. Also, since BLT may be effective in a 
short time period, the risks associated with maternal depression (such as lower 
birth weight) may be diminished. 
BLT would benefit society, since BLT has lower costs than treatment with 
antidepressant medication or psychotherapy. 
Finally, since this RCT would be the first to study the effects of BLT in the infant, it 
would contribute to the understanding of the role of BLT, depression and the 
maternal HPA-axis in the developing foetus.  
Thus, if BLT reduces depressive symptoms in pregnant women, it will provide an 
alternative, non-pharmalogical treatment for psychotherapy and antidepressant 
medication in treating antepartum depression. BLT combines direct availability, 
sufficient efficacy, low costs and high safety, taking the safety for the unborn child 
into account as well. Moreover, it does not require good language skills and it can 
be administered at home. These considerations make BLT for treating depression 
in pregnant women relevant, especially in urban multi-ethnic populations with high 
prevalence of depression and a low level of personal resources. 
 
List of abbreviations 
ACTH: adrenocorticotrophic hormone; BLT: bright light therapy; CRF: 
adrenocorticotrophic hormone-releasing factor; DLMO: Dim Light Melatonin Onset; 
DRLT: dim red light therapy; DSM = Diagnostic and Statistical Manual of Mental 
Disorders; EPDS: Edinburgh Postnatal Depression Scale; GP: general practitioner; 
GR: glucocorticoid receptor; HAM-D: Hamilton Rating Scale for Depression; HPA: 
hypothalamus-pituitary-adrenal gland; MABS: Mother and Baby Scales; MCTQ: 
Munich Chronotype Questionnaire; PSQI: Pittsburgh Sleep Quality Index; PVN: 
paraventricular nucleus; SCID: Structured Clinical Interview for DSM disorders; 
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SIGH-SAD: Structured Interview Guide for the Hamilton Depression Rating Scale – 
Seasonal Affective Disorder version.  
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Abstract 
Various risk factors have been identified for antepartum depression. This study 
evaluated seasonal influences on antepartum depressive symptoms. Data of 2,438 
pregnant women on current depressive symptoms was obtained from a large-scale 
cross-sectional study in The Netherlands. Most women were screened during the 
first trimester. Depressive symptoms were assessed using the Edinburgh Postnatal 
Depression Scale (EPDS) and dichotomized using ≥9 as cut-off score. The 
seasonal relationship between antepartum depressive symptoms and the month of 
assessment was estimated by fitting a sinusoidal curve to the data. A total of 323 
women (13.2%) scored above cut-off. In the full sample, we found no significant 
evidence for seasonal influences on depressive symptoms after adjusting for 
confounders. Additionally, we found that the seasonal influence was obscured by 
the modification of the effect by current treatment status. In women untreated for 
psychiatric complaints, we found a minimum of depressive symptomatology in 
September and a maximum in March. In women treated for psychiatric complaints 
we found a minimum of depressive symptomatology in December and a maximum 
in June. Thus, the effects of seasonality are apparent, but opposite in treated and 
untreated women. However, health professionals should be aware of depressive 
symptoms the whole year through. 
 
Key words 
Antepartum depression; Depression; Depressive disorder; Seasonal affective 
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Introduction 
Antepartum depression is a common and high impact disease, with major impact 
on both maternal and fetal health, as well as infant development [1, 2]. Women 
who suffer from antepartum depression are more likely to experience postpartum 
depression as well [3]. Children who are exposed to maternal depression during 
pregnancy have a higher risk of adverse birth outcomes, such as prematurity and 
being small for gestational age, and more often show cognitive, emotional and 
behavioural problems in childhood, adolescence and adulthood [4-6]. One of the 
possibilities to prevent these negative outcomes for mother and child is to target 
women at risk for antepartum depression. Possible treatment options are different 
forms of psychotherapy and alternative forms of therapy such as bright light 
therapy [7, 8]. The use of antidepressant medication in the peripartum period is still 
controversial and guidelines are not always consistent [9]. 
Several risk factors for antepartum depression have been identified, such as major 
life events, lack of social support, marital difficulties, low socio-economic status, 
young maternal age and an unplanned or unwanted pregnancy [10, 11]. In 
addition, a recent study showed that seasonal influences might impact the severity 
of antepartum depressive symptoms [12]. Seasonal influences on affective 
disorders have been widely recognized and are prerequisite for diagnosing 
seasonal affective disorder [13]. Seasonal affective disorder is characterized by 
recurrent depressions during fall and winter, with full remissions in spring and 
summer [14-16]. However, not all SAD cases are characterized by depression 
during fall and winter [17, 18]. 
Seasonal influences have been suggested in antepartum depressive symptoms 
[12], as well as during the postpartum period [19-24], although not consistently [25-
27]. Corral et al. (2007) found that twice as many women with postpartum 
depression suffered from seasonal affective disorder compared to healthy controls. 
Other studies found more cases of postpartum depression in autumn and winter 
months, compared to summer [19-21, 23]. Weobong et al. (2015), who studied a 
population in rural Ghana, reported an associated risk of postpartum depression 
when giving birth in the dry season . However, Panthangi et al. (2009) found no 
consistent seasonal pattern in depressive symptoms, which was confirmed by 
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Jewell et al. (2010) and Henriksson et al. (2017). An explanation for these 
contradictory findings might be sought in geographical location, assessment 
method and clinical characteristics of the women, such as the presence of 
psychosocial risk factors or the presence and type of mental illness, moderating 
seasonal influences.  
Here, we want to study potential seasonal influences on antepartum depressive 
symptoms and whether these influences differently impact subgroups of women, 
such as with or without a history of mental illness. The study is embedded in a 
population-based cross-sectional study of 2,438 pregnant women. For this 
purpose, we will study depressive symptoms in these women during the different 
months. Since seasonal influences on depressive symptoms have been found 
earlier both ante- and postpartum, we hypothesize that the prevalence of 
antepartum depressive symptoms will be higher in winter months.  
 
Methods 
Participants 
Data used for this study was collected in the context of two large-scale 
observational research projects aimed at identifying women with psychopathology, 
psychosocial problems and substance use in routine obstetric care [28, 29]. 
Collection took place mainly in rural and urban regions in the southwest of the 
Netherlands and in two cities in the south and the east part of the Netherlands [28, 
29]. The Netherlands is a small country located between 51-53º longitude and 4-7º 
latitude with a temperate maritime climate and high humidity (62-85%). 
For this purpose, women attending an antenatal check-up at one of the 
participating midwifery practices and obstetric units were invited to fill out a (digital) 
screener, the Mind2Care questionnaire [30]. The women were informed that the 
questionnaire would result in an intervention suggestion, if problems would present. 
Answers to the questionnaire were coded. After completion of the questionnaire, a 
risk profile was calculated which would potentially result in an intervention advice. 
This advice was subsequently discussed with the caregiver, which could refer or 
provide the women with other specific care.  
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Women were eligible when they were pregnant at the time of screening. Exclusion 
criteria included having a miscarriage at the time of screening, insufficient 
proficiency in Dutch and insufficient mental capability to complete the questionnaire 
independently.  
Most women (45.0%) were screened during the first trimester, 39.7% during the 
second and 15.3% during the third trimester. Screening took place between April 
2011 and December 2015. Detailed information on sampling and recruitment has 
been published elsewhere [28, 29]. 
Datasets were combined (n=2758 and n=2087). Duplicate cases and cases with 
missing data were removed (n=2407). In total, we were able to include the data of 
2,438 pregnant women in our analyses. The number of assessments ranged from 
105 to 554 participants per month and from 419 to 1,011 per season. These 
differences are partially explained by the variation of birth rates throughout the year 
[31] and periodical differences, such as holidays. 
A drop-out analysis was not possible. The data for the present study stem from an 
implementation study, for which the screening questionnaire was implemented in 
routine clinical care in midwifery clinics. 
 
Ethics 
The earlier described studies in which the present study is embedded [28, 29] have 
been conducted in accordance with the Helsinki Declaration. Because of the 
observational nature of the study, especially articles 24 (privacy and confidentially) 
and 25-32 (informed consent) are relevant. Written informed consent was obtained 
from all participants. Study protocols were approved by the medical ethical 
committee of the Erasmus University Medical Centre, Rotterdam, The Netherlands. 
The medical ethical committee deemed formal approval not necessary for the 
present study (registration number MEC-2016-332). 
 
Method 
The Mind2Care consists of 33 items which cover socio-demographic and obstetric 
factors and three symptomatology domains: psychopathology, psychosocial 
problems and substance use. Within the psychopathology domain, the Edinburgh 
Postnatal Depression Scale (EPDS) is included [32, 33]. Depressive symptoms 
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during pregnancy were assessed using the EPDS. This structured 10-item self-
report questionnaire is developed as a screening tool for postpartum depressive 
symptoms [32], but is validated for the antepartum period as well [33]. Each item is 
scored 0-3, resulting in a sum score of 0-30 [32]. Higher scores represent more 
symptomatology. Depending on trimester, sensitivity and specificity of the EPDS 
range from 70-79% and 94-97%, respectively [32]. Since EPDS scores were non-
normally distributed, with 61.4% of women scoring below 5, EPDS sum scores 
were dichotomized using a cut-off of 9 (indicating at least mild depressive 
symptoms) [34]. With this cut-off, sensitivity and specificity range from 76-97% and 
92-94%, respectively [33]. A alternative cut-off of 13 (at least moderate depressive 
symptoms) was used for additional comparisons with other literature [34]. 
The month of EPDS assessment was used in this study for analyses as a measure 
for seasonality.  
In line with literature on risk factors of antepartum depression [10, 11], the following 
potentially confounding factors were assessed: 
 Socio-demographic: age, ethnicity, educational level, employment status, 
marital status. 
 Obstetric: gestational age at assessment, parity. 
 Psychopathology, psychosocial problems and substance use: support from 
partner and environment, relational problems, financial problems, housing 
problems, unplanned or unwanted pregnancy, smoking, alcohol use, drug 
use, current and past domestic violence, use of psychiatric/sleep 
medication, psychiatric admission in history, current (pharmacological or 
non-pharmacological) treatment for psychiatric problems. 
 
Statistical analysis 
We used logistic regression analysis to estimate the impact of month of 
assessment on antepartum depressive symptoms. For this purpose, we fitted a 
sinusoidal curve to the data by including a sine and cosine function to the 
regression model. The joint sine-cosine effect was tested using a Chi-Square Test 
[35]. This method is referred to as harmonic analysis and is often used to describe 
periodical patterns in epidemiological research [31, 36-38] and more recently, also 
psychiatric research [39]. Next, we tested whether the addition of a second 
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sinusoidal curve significantly improved the fit of the model. Analyses were repeated 
adjusting for confounding variables. Confounding variables were defined as having 
a significant univariable relationship with antepartum depressive symptoms, having 
an univariable relationship with month of assessment, and were not part of the 
causal pathway between month of assessment and antepartum depressive 
symptoms [40]. We report crude and adjusted odds ratio (OR) and standard error 
of the sine and cosine function, curve-shift and amplitude. 
Finally, we explored whether the impact of month of assessment on antepartum 
depressive symptoms was modified by any of the assessed patient characteristics. 
For this purpose, we adopted the following procedure. First, we tested whether 
patient characteristics could be considered a risk factor of antepartum depressive 
symptoms using univariable logistic regression analysis. Interaction terms between 
significant patient characteristics with sine and cosine functions were calculated. 
We then added the sine and cosine interaction terms to a multivariable logistic 
regression model, including the sine and cosine functions, and confounding 
variables. For the specific aim of interpreting a significant interaction term (based 
on a significant Chi-Square Test of the joint sine-cosine interaction terms) and 
antepartum depressive symptoms, we stratified the sample in subgroups by patient 
characteristic, repeated the main analysis, and reported the direction and 
magnitude of seasonal influence within the thus formed patient subgroups. Patient 
characteristics between subgroups with significant interaction effect were 
compared using Chi-Square test. 
Data was analyzed using SPSS 24.0 (IBM Corporation, Chicago, IL, USA). 
Statistical significance was defined as p < 0.05.  
 
Results 
An overview of background characteristics is shown in Table 4.1. 
The median EPDS scores by month are shown in Table 4.2. The overall median 
EPDS score was 3 (interquartile range (IQR) 1-6; range 0-28). In this sample, 323 
women (13.2%) scored EPDS ≥ 9 (at least mild depressive symptoms), of which 92 
(3.8%) scored ≥ 13 (at least moderate depressive symptoms). The proportions by 
month of year are displayed in Figure 4.1 and Table 4.2.  
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Table 4.1 – Overview of background characteristics. 
Characteristics Mean (SD) or N (%) 
Age: 30.0 years (± 4.6, range 15-44) 
  
Gestational age: 17.1 weeks (± 9.0, range 2-41) 
  
Ethnicity:  
Dutch 2158 (88.5%) 
European 84 (3.5%) 
Dutch Antillean 31 (1.3%) 
Surinamese 28 (1.2%) 
Moroccan 28 (1.2%) 
Turkish 20 (0.8%) 
Other 85 (3.5%) 
  
Marital status:  
Married/cohabiting 2393 (98.2%) 
Single 44 (1.8%) 
  
Education:  
Primary education 120 (5.0%) 
Secondary education 1057 (43.8%) 
Higher education 1234 (51.2%) 
  
Employment:  
Employed 2043 (84.1%) 
Unemployed 386 (15.9%) 
  
Parity:  
Primigravida 1838 (76.0%) 
Multigravida 580 (24.0%) 
  
Pregnancy intention:  
Wanted to get pregnant 2395 (98.8%) 
Did not want to get pregnant 
(yet) 
29 (1.2%) 
  
Relationship status:  
In relationship 2393 (98.2%) 
Single 44 (1.8%) 
  
Note: variance in sample size, due to missing data. 
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Figure 4.1 – Proportion of EPDS ≥ 9 by month. 
 
Table 4.2 – Number of participants, median, IQR and proportions of participants with 
of EPDS scores of ≥ 9 by month of year. 
Month N Median (IQR) EPDS ≥ 9 (%) 
January 140 3 (1-6) 10.7 
February 138 4 (2-7) 17.4 
March 305 4 (1-7) 17.1 
April 554 4 (2-7) 13.9 
May 201 3 (1-7) 13.4 
June 156 3 (1-7) 15.4 
July 200 3 (1-6) 12.0 
August 170 3 (1-5) 10.6 
September 171 3 (1-6) 10.5 
October 156 3 (1-6) 10.9 
November 105 3 (1-6) 12.4 
December 142 3 (1-6) 9.2 
    
Total 2,438 3 (1-6) 13.2 
    
N = number of participants; IQR = interquartile range; EPDS = Edinburgh Postnatal Depression Scale. 
 
We fitted a model with one and with two sinusoidal curves. A second curve did not 
further improve fit of the model. We found statistical evidence for a sinusoidal 
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pattern of depressive symptoms by month of assessment (sine-function βcrude=.224 
[SE=.084], p=.007; cosine-function βcrude=-.014 [SE=.097], p=.888; joint sine-cosine 
function Chi2 (2)=7.369, p=.025). This corresponds with a maximum of depressive 
symptomatology in March (estimated prevalence of 15.0%), and a minimum of 
depressive symptomatology in September (estimated prevalence of 10.4%). After 
adjustment for confounders (age, educational level, and ethnicity), we no longer 
found statistical evidence for a sinusoidal pattern of depressive symptoms by 
month of assessment (sine-function βadjusted=.176 [SE=.086], p=.041; cosine-
function βadjusted=-.036 [SE =.099], p=.720; joint sine-cosine function Chi2 (2)=4.377, 
p=.112). 
 
Modifying factors 
The risk factors that showed a significant relationship with the dichotomized EPDS 
score included employment status, unplanned or unwanted pregnancy, smoking, 
marital status, support from partner and environment, relational problems, financial 
problems, housing problems, present and past domestic violence, use of 
psychiatric/sleep medication, and current treatment for psychiatric problems. Next, 
we studied whether the impact of seasons on depressive symptoms might have 
been obscured by a modification of the effect by patient characteristics. Of all 
characteristics tested, one patient characteristic showed a significant moderating 
effect, i.e. being under current treatment for psychiatric problems (Chi2(1)=6.431; 
p=.040). Adjusted for confounders, for women not receiving treatment (n=2309), 
we found a significant effect of seasonality (sine-function βadjusted=.267 [SE=.096], 
p=.005; cosine-function βadjusted=.070 [SE=.108], p=.516; joint sine-cosine function 
Chi2(2)=8.521, p=.014), corresponding to a maximum of depressive 
symptomatology in March (estimated prevalence of 14.5%) and a minimum of 
depressive symptomatology in September (estimated prevalence of 7.8%). For 
women receiving treatment (n=91), we also found a significant effect of seasonality 
(sine-function βadjusted=-.075 [SE=.312], p=.810; cosine-function βadjusted=-.941 
[SE=.391], p=.016; joint sine-cosine function Chi2 (2)=6.254, p=.044). This 
corresponds to a maximum of depressive symptomatology in June (estimated 
prevalence of 73.7%) and a minimum of depressive symptomatology in December 
(estimated prevalence of 38.4%). The unadjusted joint sine-cosine function of 
Seasons and depressive symptoms during pregnancy 
 
105 
 
month of assessment on depressive symptoms (EPDS ≥ 9) for treated and 
untreated women expressed in Odds Ratio is shown in Figure 4.2.  
No modifying effects were found for any of the other patient characteristics. 
 
 
 
 
Figure 4.2 – Joint sine-cosine function of month of assessment on depressive 
symptoms (EPDS ≥ 9) expressed in Odds Ratio, shown for women who did not receive 
treatment (black) and women who did receive treatment for psychiatric problems 
(grey).  
Function is unadjusted for confounders (age, educational level and ethnicity). 
 
Treated versus untreated women 
In order to better understand why treated women show a deviant periodical pattern 
of depressive symptoms, we explored the socio-demographic and clinical 
characteristics of this group of women. In post-hoc analyses, patient characteristics 
of treated women were compared to untreated women. First, as might be expected, 
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treated women more often than untreated women used psychiatric and/or sleep 
medication during pregnancy (p<.001; 22% versus 1.5%), and more often had a 
history of psychiatric admission (p<.001; 8% versus 1.1%). Treated women also 
smoked cigarettes more often during pregnancy (p<.001; 16% versus 5.2%). Next, 
they were more often single (p=.006; 6.5% versus 1.6%) or experienced 
relationship problems (p<.001; 21.7% versus 3.0%), including abuse (p<.001; 1.1% 
versus 0.1%). Finally, unemployment (p<.001; 33.0% versus 15.2%) and financial 
problems (p<.001; 20.9% versus 5.0%) were more prevalent, and they experienced 
less support from their environment (p=.028; 7.1% versus 2.3%). 
 
Discussion 
The present study used a large dataset of 2,438 pregnant women to explore 
seasonal differences on antepartum depressive symptoms. We found a prevalence 
of 13.2% of clinically relevant antepartum depressive symptoms, in agreement with 
previous research [2]. In the full study sample, we found no statistical evidence for 
a sinusoidal pattern of antepartum depressive symptoms by month of assessment, 
after adjusting for confounders. However, we found that the effect of month of 
assessment was modified by whether or not women were currently treated for 
psychiatric problems. Women who did not receive treatment for psychiatric 
problems showed a significant seasonal effect with a minimum of depressive 
symptomatology in September and a maximum in March, as hypothesized. Treated 
women also showed a significant seasonal effect, with a maximum of depressive 
symptomatology in June and a minimum in December. 
Consistent with previous research on seasonal affective disorder [14-16], a 
seasonal pattern was found in women not receiving treatment for psychiatric 
problems. However, in a recent study in the general population, consisting of 
34,294 respondents, the authors could not find a relation between depressive 
symptoms and latitude, season, and sunlight, thereby questioning the validity of 
seasonal affective disorder [41]. The findings of this study were however refuted 
because of several methodological and rational shortcomings, such as not 
including patient history and their cross-sectional approach [42]. 
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Meliska et al. (2013) hypothesized that seasonal influences might contribute to 
worsening of already existing depressive symptoms, rather than being the cause of 
antepartum depressive symptoms. The findings of this study are partly in line with 
this hypothesis, with significant seasonal influences in women receiving treatment 
for psychiatric problems (both pharmacological and non-pharmacological). 
However, it is unexpected to find a maximum of depressive symptomatology in 
June and a minimum in December. Therefore, if there is a seasonal effect indeed, 
the seasonal effects in this subgroup of pregnant women might not be caused by 
light conditions, but are rather the result of other factors, such as temperature and 
humidity. Two earlier studies conducted in a tropical climate showed an increase in 
depressive symptoms in summer, due to temperature and humidity [43, 44]. 
However, if this would be the case, one might expect to find these effects in 
untreated women as well. Therefore, we do not find this hypothesis plausible. We 
found significant differences between treated and untreated women. However, 
these characteristics, such as smoking and financial problems, are often seen in 
psychiatric patients and are therefore not necessarily a cause for the seasonal 
effects in this subgroup of women. Possibly, social factors might contribute to 
seasonal fluctuations of self-reported depressive symptoms. For example, women 
might experience less social support in the summer, when family, neighbors and 
caregivers may be gone for vacation. Since the group of treated women shows 
more psychosocial problems, it may be that they are more reliant on social support. 
Possibly, women with a fear of delivery might have an exacerbation of their 
symptoms, because there are staff shortages during the summer months and they 
might not receive the same level of care and support. However, future research is 
needed to gain more insights regarding these social factors. However, one must 
keep in mind that patients with seasonal affective disorder are not necessarily 
worse in winter [17, 18]. 
The study by Meliska et al. (2013) is the only study thus far studying seasonal 
patterns in antepartum depression. As mentioned earlier, the results of this study 
are partly in line with their hypothesis. However, they only found a seasonal pattern 
in women suffering from antepartum depression and not in healthy controls. A 
possible explanation for this discrepancy with the present study might be sought in 
differences in study design and/or statistical analyses. In addition, the depressed 
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patients from the study by Meliska et al. (2013) were not allowed to use 
medication, which was not the case in our study, which might have influenced our 
results. 
Interestingly, studies exploring seasonal effects during the postpartum period found 
higher prevalences of depression, compared to the present study exploring the 
effects during pregnancy [21, 23, 26]. An explanation might be found in the study 
population studied in this study: 51.2% of women attended higher education and 
88.5% was native Dutch, indicating that this is a relative low risk sample, fitting with 
a lower prevalence of severe depressive symptoms. Also, different factors in the 
postpartum period might play a role in the increase of depressive symptoms, such 
as sleep deprivation and hormonal fluctuations.  
An earlier study did not find a seasonal pattern in depressive symptoms in the 
general population when using a general questionnaire, as opposed to our study 
[45]. However, when using a specific questionnaire, the Seasonal Pattern 
Assessment Questionnaire, a seasonal pattern was found in the same population 
[46]. Therefore, we consider the possibility that our use of a general questionnaire 
has resulted in an underestimation of the seasonal effect. 
Consistent with previous research, several risk factors were found for antepartum 
depressive symptoms, such as lack of social support, smoking during pregnancy 
and an unplanned or unwanted pregnancy [10, 11]. However, current treatment for 
psychiatric problems was the only risk factor showing a moderating effect between 
month of assessment and EPDS score. Age, educational level and ethnicity 
emerged as confounders of the relationship between seasonality and depressive 
symptoms. We hypothesize that these socio-demographic factors are related to 
planning of pregnancy. For example, high risk women (young, low educational level 
and from non-Dutch origin) might be more likely to become pregnant during the 
holiday. 
 
Strengths and limitations 
One of the strengths of this study is the large study sample of 2,438 respondents – 
with a prevalence in depressive symptomatology comparable to previous studies – 
which allows revealing small and modifying effects. Second, the EPDS is a 
validated tool for screening antepartum depression and is used worldwide. Finally, 
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this is one of the first studies to use a sine-cosine function to describe the 
relationship between seasonality and depressive symptomatology, which is 
specifically suited to describe periodic patterns. Also, by including confounding and 
modifying factors into our analysis, we were able to bring previous contradictory 
results into concordance. 
There are limitations to this study. First, the EPDS is a self-assessment 
questionnaire and is not a clinical diagnosis for depression. Second, the EPDS 
only asks about depressive symptoms over the past week and does not assess 
level of impairment in daily life due to depressive symptoms. Further, a cross-
sectional study may be less suitable to study the prevalence of antepartum 
depressive symptoms, since seasonal influences are possibly mainly experienced 
as an intra-individual course and as a result may be difficult to detect on a 
population level. Consequently, future research should study prevalence and 
severity of antepartum depressive symptoms in a longitudinal study, which allows 
following participants across seasons to determine whether they are vulnerable to 
seasonal influences. Because of the cross-sectional nature of the study, we have 
no information about the start or the length of the depressive episode or treatment. 
Further, we found low prevalences of EPDS ≥ 13 (3.8%) and are therefore 
underpowered to detect small seasonal effects in severe cases. Therefore, we 
conducted analyses with a lower cut-off. Finally, we might have found spurious 
effects. However, we were not able to perform a sensitivity analysis that could 
support our findings, which we suggest for future research. 
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Abstract 
Poor sleep quality during pregnancy is associated with both antepartum and 
postpartum depression and adverse birth outcomes. This study evaluated both 
objective and subjective sleep quality and the effects on the subsequent course of 
antepartum depressive symptoms in psychiatric patients. This observational 
explorative study was embedded in an ongoing study focusing on pregnant women 
with a mental disorder and was performed in 18 patients (24–29 weeks pregnant). 
Depressive symptoms were assessed throughout pregnancy using the Edinburgh 
Postnatal Depression Scale (EPDS) with 5-week intervals. Sleep was assessed 
with actigraphy, the Pittsburgh Sleep Quality Index (PSQI) and sleep diaries at the 
start of the study. We studied correlations between sleep parameters and EPDS 
scores cross-sectionally using Spearman correlation. Next, we studied the course 
of antepartum EPDS scores over time per sleep parameter using generalized linear 
mixed modelling analysis. Objectively measured fragmentation index, total PSQI 
score and 4 PSQI subscales (sleep quality, sleep duration, sleep disturbances and 
daytime dysfunctions) were significantly correlated with EPDS scores when 
measured cross-sectionally at the start. Six objectively and subjectively measured 
sleep parameters had moderate to large effects on the course of depressive 
symptoms through the third trimester, but these effects were not statistically 
significant. More research is necessary to explore the causality of the direction 
between sleep problems and antepartum depressive symptoms we found in 
psychiatric patients. 
 
Keywords 
Sleep; Circadian rhythm; Depression; Depressive disorder; Antepartum 
depression; Pregnancy 
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Introduction 
Depression during pregnancy is a common and high impact disease, with a 
prevalence of approximately 11–13% [1]. Antepartum depression has a major 
impact on both maternal and fetal health, as well as infant development. Children 
exposed to maternal depression during pregnancy have a higher risk of adverse 
birth outcomes and more often show cognitive, emotional and behavioral problems 
[2–4]. 
Many risk factors for antepartum depression have been identified, such as major 
life events, lack of social support, marital difficulties, low socio-economic status and 
an unplanned or unwanted pregnancy [5,6]. Moreover, sleep problems are 
common in pregnancy [7,8]: pregnant women typically show disturbed, 
desynchronized circadian rhythms, resulting in disturbed sleep patterns, which put 
them at risk for depression [9]. Poor sleep quality during pregnancy is associated 
with both antepartum and postpartum depressive symptoms and adverse birth 
outcomes [10–17], although a causal relation is difficult to prove due to the 
reciprocal relation of depression and sleep. 
The association between poor sleep quality and mental disorders has long been 
recognized in the general population [18,19] and has also been shown in the 
peripartum period. However, many studies only studied the postpartum period 
[20,21] and/or only studied self-reported measures [10,12,22–24]. Earlier research 
showed that subjective sleep quality is worse than objectively measured sleep 
quality in pregnant women with a mental disorder [25]. A study in healthy women 
showed indeed that subjective sleep quality was associated with postpartum mood 
disturbances, but not objectively measured sleep quality [26]. However, two other 
studies in healthy pregnant women found that both objective and subjective sleep 
parameters were significantly associated with depressive symptoms in the third 
trimester and postpartum [15,17]. Since these three studies were executed in 
healthy women, these results cannot be simply extrapolated to pregnant women 
with a psychiatric disorder. This is relevant, since these women are at high risk for 
sleep problems because of not only their pregnancy, but also because of their 
mental problems. Based on the reciprocal relation between depression and sleep, 
it is relevant for clinicians and researchers to learn whether sleep problems during 
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pregnancy are associated with depressive symptoms in psychiatric patients and 
whether these predict the longitudinal course of depressive symptoms. 
Here, we explored both subjective and objective sleep parameters and their effects 
on the course of antepartum depressive symptoms in a sample of 18 psychiatric 
patients. We hypothesized that antepartum sleep quality is associated with 
antepartum depression symptom severity when assessed simultaneously during 
pregnancy and with its subsequent course. For this purpose, we studied both 
objectively measured sleep parameters from actigraphs and subjectively measured 
sleep parameters in relation to the course of depressive symptoms in pregnant 
women diagnosed with a mental disorder. 
 
Materials and Methods  
Participants 
This study was embedded in a larger randomized controlled trial (DAPPER, 
NTR3015, http://www.trialregister.nl). The DAPPER study (Daycare Alternative 
Psychiatric Pregnant women Efficiency Research) aimed to evaluate the 
effectiveness of a group-based multicomponent psychotherapy intervention for 
pregnant women with a mental disorder, compared to individual counseling (care 
as usual). Both arms showed similar effects on depressive symptoms [27]. Eligible 
participants were pregnant women, diagnosed with a mental disorder, confirmed by 
the Structured Clinical Interview for DSM-IV diagnosis by one trained medical 
doctor [28]. A convenience subsample of participants was recruited to perform the 
actigraphy, PSQI and sleep diary assessments between 24 and 29 weeks of 
pregnancy. Participants were recruited in the second trimester, since sleep is more 
affected by pregnancy in the third trimester [29]. Exclusion criteria were suffering 
from a tremor or somatic conditions that could affect sleep, or an insufficient 
proficiency in Dutch. 
 
Ethics 
The study protocol of the randomized controlled trial was approved by the Medical 
Ethical Committee of the Erasmus University Medical Centre in Rotterdam, the 
Netherlands (registration number MEC-2009-370). Written informed consent was 
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obtained from all participants. The present study was added to the protocol after 
ethical approval of the amendment. 
 
Method 
The following demographic information was obtained from all participants: Age, 
gestational age, parity, marital status, ethnicity, educational level and employment 
status. Educational level was dichotomized into high and low educational level, with 
low educational level defined as basic vocational education or less.  
Objective sleep parameters were measured using the Actiwatch Actigraphy model 
AW4 (Cambridge Neurotechnology Ltd, Cambridge, UK). Actigraphy, the 
continuous assessment of activity with a watch-sized non-dominant wrist-worn 
recorder, is a validated technique to obtain estimates of sleep [30–32]. The 
Actiwatch measured the number of movements above a threshold setting of 20 
activity counts per 60 seconds epoch, and the following indices were extracted: 
Total sleep time, sleep latency (time until asleep), sleep efficiency (percentage of 
time spent asleep while in bed) and the fragmentation index (the addition of 
percentage time spent moving and the percentage immobility phases of 1 minute). 
Lower total sleep time, higher sleep latency, lower sleep efficiency and higher 
fragmentation index indicate more sleep problems. Sleep data were analysed using 
the Actiwatch Sleep Analysis program (version 1.16, Cambridge Neurotechnology 
Ltd, Cambridge, UK). Participants wore the Actiwatch for 7 consecutive days and 
nights at the start of the study. Only the weekdays (≥3 days and nights) were used 
for analyses because of an increase in variability during the weekends. The 
precision of this assessment period was better than for 7 days [25]. 
Subjective sleep parameters were measured at the start with the PSQI, a 
structured 19-item self-rating questionnaire with 5 additional items reported by 
bedpartner, that assesses sleep quality and disturbances of the past month [33]. 
The overall sum score ranges from 0–21, with higher scores corresponding to poor 
sleep quality [33]. A sum score of >5 indicates poor sleep quality. The PSQI has a 
sensitivity and specificity of respectively 89.6% and 86.5% in distinguishing good 
and bad sleepers [33]. The 19 self-rated items generate 7 component scores: 
subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, 
sleep disturbances, use of sleeping medication and daytime dysfunction [33]. 
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Subscale scores range from 0–3, with higher component scores indicating more 
sleep problems [33]. 
Furthermore, we measured subjective sleep quality with sleep diaries kept by the 
participants. Participants kept a sleep diary during the week of the actigraphy 
assessments, which included questions on sleep time and sleep latency. A 
minimum of 3 weekday measurements of each participant were averaged, in 
analogy with the sleep parameters measured by the Actiwatch. 
Depressive symptoms were assessed with the EPDS at the start of the study and 
subsequently at 5-week intervals until the end of pregnancy, thus 5, 10 and 15 
weeks after the start. The EPDS is a structured 10-item self-report measure of 
depression during pregnancy [34]. Items are scored with a value 0–3, resulting in a 
sum score of 0–30 [34]. The EPDS was developed for the detection of postpartum 
depression, but has been validated for screening depression during pregnancy as 
well [35]. Using a cut-off of 10 or 11, depending on the trimester studied, sensitivity 
and specificity of the EPDS for screening antepartum depression range between 
respectively 70–79% and 94–97%, [35]. In the second and third trimester, a score 
above 10 indicates clinically relevant symptoms of depression [35]. 
 
Statistical analysis 
With Spearman correlation coefficients, we tested whether the various sleep 
parameters were correlated with EPDS scores at the start of the study. A 
correlation of <0.3 indicates no or a very weak relationship, of 0.3–0.5 a weak, of 
0.5–0.7 a moderate and of >0.7 a strong relationship [36]. 
We estimated the course of antepartum EPDS scores over time using generalized 
linear mixed models. This is a statistical technique that, especially in the context of 
longitudinal designs, is robust for missing data [37], particularly in case of missing 
at random (MAR) and missing completely at random (MCAR). In a series of 
random-intercept models, we included time, the standardized sleep parameter and 
the time x standardized sleep parameter interaction as an effect measure of a 
sleep parameter on the course of antepartum EPDS scores. Subsequently, we 
added the standardized score of EPDS measured at the start to the model, since 
depression severity is an important predictor for treatment outcome [38]. For the 
total PSQI score, we also tested the dichotomized PSQI score, using the validated 
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cut-off of >5 [33]. Standardized regression coefficients including the 95% 
Confidence Interval (CI) are reported. Regression coefficients reflect the slope of 
the regression line. For example, in the case of a regression coefficient of 0.15, an 
increase of 1 standard deviation (SD) by the sleep parameter reflects an increase 
of 0.15 SD on the EPDS score per measurement, thus after 5 weeks. A negative 
coefficient reflects a decrease in symptom severity and a positive coefficient an 
increase. A coefficient of <0.2 indicates a small effect, around 0.5 a moderate 
effect and of >0.8 a large effect [36]. By means of sensitivity analyses, we repeated 
our primary analysis adjusted separately one by one for medication, treatment arm, 
psychiatric diagnosis, age, education level, parity, work and ethnicity. 
Data was checked for non-normality of distribution. Patient characteristics and 
sleep parameters were summarized by their median and interquartile range (IQR) 
for ordinal and continuous variables, since these were not normally distributed. Age 
and gestational age were summarized by their mean and SD. Categorical 
variables, such as educational level, were summarized by count and proportion. 
Missing data patterns were explored. 
Data was analyzed using SPSS 24.0 (IBM Corporation, Chicago, IL, USA). 
Statistical significance was defined as p < 0.05. 
 
Results 
We studied 18 pregnant women. One EPDS score was missing at the start of the 
study, 4 at 5 weeks, 8 at 10 weeks and 13 at 15 weeks after the start. However, 5 
women were at 15 weeks ≥40 weeks pregnant. Table 5.1 shows the demographic 
characteristics of the women at the start. Ten women were primarily diagnosed 
with depression, 5 women with generalized anxiety disorder, 2 with borderline 
personality disorder and 1 with bipolar disorder. Two participants drank alcohol and 
7 participants smoked while pregnant. During the study, 4 participants used 
antidepressant medication, 1 used lithium and 1 methylphenidate. 
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Table 5.1 – Demographic characteristics of women at the start (24–29 weeks of 
pregnancy). 
Demographics Patients 
Age in years, mean (SD) 29.5 (5.3) 
Gestational age in weeks, mean (SD) 26.0 (1.7) 
Parity, nulliparous 14 (78%) 
Committed relationship 16 (89%) 
Ethnicity, non-Western 5 (28%) 
Educational level, low 13 (72%) 
Unemployed 13 (72%) 
 
Table 5.2 – Distribution of objective and subjective sleep parameters at the start (24–
29 weeks of pregnancy). 
Sleep parameters Median IQR 
Objective sleep parameters   
Actiwatch total sleep time (hh:mm) 06:40 06:01–07:36 
Actiwatch sleep latency (mm:ss) 21:46  12:03–41:59 
Actiwatch sleep efficiency (%) 78.65 76.35–84.67 
Actiwatch fragmentation index (%) 36.88 25.25–46.77 
   
Subjective sleep parameters   
PSQI total score 7.50 4.75–11.25 
PSQI sleep quality 1 1–2 
PSQI sleep latency 1 0–2 
PSQI sleep duration 0 0–1 
PSQI sleep efficiency 1 0–3 
PSQI sleep disturbances 2 1–2 
PSQI sleep medication none none  
PSQI daytime dysfunction 1 1–3 
Diary total sleep time (hh:mm) 7:55 7:09–9:20 
Diary sleep latency (mm:ss) 35:00  10:00–46:15 
h = hour; m = minute; s = second; IQR = interquartile range. 
 
At the start of the study, median EPDS score was 13 (IQR 8–19). Median EPDS 
scores were 10.5 (IQR 3.75–19.75) 5 weeks after, 13.5 (IQR 6.5–21.5) 10 weeks 
after and 20 (IQR 9.5–23) 15 weeks after the start. 
Table 5.2 shows the objective and subjective measured sleep parameters at the 
start of the study. 
Table 5.3 shows the correlations between the various sleep parameters and the 
EPDS scores at the start. A moderate relationship was found between 
actigraphically measured fragmentation index, PSQI sleep quality and PSQI sleep 
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duration and EPDS score. A strong relationship was found between total PSQI 
score, PSQI sleep disturbances score and PSQI daytime dysfunction score and 
EPDS score.  
 
Table 5.3 – Correlations between objective and subjective sleep parameters and EPDS 
scores when measured cross-sectionally at the start (24–29 weeks of pregnancy). 
Sleep parameters r (SE) 
Objective sleep parameters  
Actiwatch fragmentation index −0.51* (0.22) 
Actiwatch total sleep time 0.14 (0.25) 
Actiwatch sleep efficiency 0.41 (0.20) 
Actiwatch sleep latency 0.40 (0.26) 
  
Subjective sleep parameters  
PSQI total score 0.79*** (0.15) 
PSQI total score, dichotomized 0.78*** (0.10) 
PSQI sleep quality 0.68** (0.16) 
PSQI sleep latency 0.35 (0.26) 
PSQI sleep duration 0.53* (0.23) 
PSQI sleep efficiency −0.38 (0.22) 
PSQI sleep disturbances 0.82*** (0.13) 
PSQI sleep medication none 
PSQI daytime dysfunction 0.82** (0.12) 
Diary total sleep time −0.16 (0.26) 
Diary sleep latency 0.28 (0.29) 
SE = standard error; *p < 0.05; **p < 0.01; ***p < 0.001. 
 
Sleep efficiency, total sleep time and sleep latency were not significantly 
associated with depressive symptoms, both objectively and subjectively measured.  
Table 5.4 shows the standardized regression coefficients for the course of 
antepartum EPDS scores for the various objectively and subjectively measured 
sleep parameters. None of the sleep parameters showed a significant association 
with the course of antepartum EPDS scores, both unadjusted and adjusted for 
standardized EPDS score at the start. Sensitivity analyses, in which we separately 
adjusted for medication, treatment arm, psychiatric diagnosis, age, education level, 
parity, work and ethnicity, suggested stability of the results that we found.  
Though one should be careful interpreting the magnitudes of effects because of a 
lack of statistical significance, standardized regression coefficients differed 
between the studied sleep parameters. Moderate effects were found for PSQI total 
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score, PSQI sleep duration and sleep latency measured by diary. Large effects 
were found for PSQI sleep quality scores and total sleep time measured by both 
diary and actigraphy.  
Exploring missing data patterns did not show a specific selection of women with 
more missing EPDS assessments. 
 
Table 5.4 – Effects  of objective and subjective sleep parameters at the start (24–29 
weeks of pregnancy) on the course of depressive symptoms through the third 
trimester. 
Sleep parameters 
Standardized β (95% 
CI) 
Standardized βadj 
(95% CI)^ 
Objective sleep parameters  
Fragmentation index −0.56 (−2.39–1.28) −0.28 (−2.01–1.47) 
Total sleep time 1.23 (−0.42–2.89) 1.25 (−0.47–2.97) 
Sleep efficiency −0.03 (−1.87–1.81) −0.36 (−2.12–1.39) 
Sleep latency −0.27 (−1.60–1.06) −0.24 (−1.54–1.06) 
   
Subjective sleep parameters   
PSQI total score −0.46 (−2.29–1.38) −0.48 (−2.12–1.17) 
PSQI total score, dichotomized −0.45 (−2.10–1.20) −0.26 (−1.84–1.31) 
PSQI sleep quality 1.73 (−2.78–6.24) 1.99 (−1.01–4.98) 
PSQI sleep latency 0.41 (−1.12–1.95) 0.35 (−1.11–1.81) 
PSQI sleep duration −0.53 (−3.96–2.90) 0.72 (−1.35–2.78) 
PSQI sleep efficiency −0.19 (−1.82–1.44) 0.11 (−1.37–1.59) 
PSQI sleep disturbances 0.27 (−3.26–3.79) 0.48 (−2.25–3.20) 
PSQI sleep medication none none 
PSQI daytime dysfunction −0.36 (−4.33–3.62) −0.15 (−2.51–2.22) 
Diary total sleep time 1.12 (−0.31–2.55) 1.25 (−0.33–2.83) 
Diary sleep latency 0.70 (−0.83–2.22) 0.75 (−0.84–2.33) 
^Adjusted for standardized EPDS score at the start. 
 
Discussion 
The present study studied 18 pregnant women with a mental disorder to explore if 
and how objectively and subjectively measured sleep parameters would be 
associated with antepartum depressive symptoms. We found that actigraphically 
measured fragmentation index, total PSQI score (both continuous and 
dichotomous) and 4 PSQI subscales (sleep quality, sleep duration, sleep 
disturbances and daytime dysfunctions) were moderately to strongly correlated 
with depressive symptoms during pregnancy. We found that some sleep 
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parameters had a notable impact on the course of antepartum depressive 
symptoms during the third trimester (effect size > 0.8 SD), both unadjusted and 
adjusted for EPDS score at the start and different separate confounders 
(medication, treatment, psychiatric diagnosis, age, education level, parity, work and 
ethnicity). 
 
Cross-sectional findings 
We found a moderate to strong correlation between total PSQI score (both 
continuous and dichotomized) and 4 PSQI subscales and antepartum depressive 
symptoms, when measured cross-sectionally. Thus, women experienced more 
depressive symptoms when they showed more overall sleep problems, when they 
reported their sleep to be of poor quality, when they reported to sleep less, when 
they suffered from more various sleep disturbances or when they had more 
problems with functioning during the day.  
The finding that women who report more depressive symptoms also suffer from 
specific sleep problems is congruent with the relation with the total PSQI score, 
since this sleep parameter is an overall measure of these various underlying sleep 
problems. With respect to daytime dysfunctioning, it is not surprising that these 
symptoms correlate with depressive symptoms, since daytime dysfunctioning is a 
symptom of depression [28].  
Two previous cross-sectional studies in peripartum women using the PSQI find 
associations between sleep parameters and depressive symptoms, although not 
consistently [23,24]. However, both these studies were executed in postpartum 
women, who have shown to experience more sleep problems than pregnant 
women [39]. 
We found a statistically significant negative correlation between actigraphically 
measured fragmentation index and antepartum depressive symptoms, when 
measured in the second trimester at the start of the study. Thus, women reported 
more depressive symptoms when the Actiwatch measured a lower fragmentation 
index, indicating lower mobility during sleep. This is not in line with earlier studies, 
where a positive relation is found between depressive symptoms and fragmented 
sleep [13,17,22]. Depressive symptoms are common in adults with nighttime 
restlessness, such as (both pregnant and non-pregnant) patients with Restless 
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Legs Syndrome [40]. We have no explanation for this contradictory finding. We are 
studying a complex population where different mechanisms may be at stake. To 
our knowledge, sleep studies with actigraphy have not been executed earlier in a 
pregnant psychiatric population, so we cannot compare our findings to those from 
other studies. Future research should be executed to confirm our findings. 
In this study, we found that the majority of the patients was suffering from sleep 
problems, which is common in pregnancy [7,8]. The mean PSQI score was 7.5, 
with 14 out of 18 patients scoring 5 or higher, an indication of clinically relevant 
sleep problems [33]. This score is high, but comparable to other studies 
peripartum. Even in studies among healthy pregnant and postpartum women 
without psychiatric disorders, mean PSQI scores were rather high, ranging from 6.3 
to 8.3 [10,15,24,26]. A recent meta-analysis among 24 articles showed that the 
average PSQI score in pregnancy was 6.1 and that it increases from second to 
third trimester [29]. This indicates that sleep problems among pregnant women are 
very common. Possibly, a higher PSQI cut-off to distinguish bad sleepers is 
needed during pregnancy [29]. 
 
Longitudinal findings 
None of the sleep parameters were significantly associated with the course of 
antepartum depressive symptoms. However, we did find differences in 
standardized regression coefficients. Though not significant, probably due to the 
small sample size, we found large effects for PSQI sleep quality and total sleep 
time measured by both diary and actigraph, which may be an indication of the 
direction and magnitude of the effect. However, a study with more statistical power 
would be necessary to confirm these findings. A post-hoc power analysis revealed 
that a sample size of 64 women would have been needed to show significance. 
Another explanation for not finding any significant effects may be the fact that all 
women in this study were treated for their depressive symptoms, which, as a 
consequence, could have positively affected the course of these symptoms. At 
present, such studies have not been conducted yet in a population of pregnant 
women diagnosed with a mental disorder. Thirdly, another explanation might be the 
timing of assessment. Studies with antepartum measurements studied the third 
trimester [10,15,17,26], a timing which is comparable to our study. However, the 
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third trimester is 12 weeks long and sleep may therefore be influenced differently 
along the trimester, since mothers have more sleep problems as the third trimester 
progresses, with women having more difficulty finding a comfortable sleeping 
position [7]. Adjustment for gestational age did not show that this influenced sleep 
in our patients differently. However, the effects of this may be small and a larger 
study sample may be necessary to find this. For these reasons, it is difficult to 
generalize our and other findings to the third trimester as a whole. 
 
Strengths and limitations 
One of the strengths of this study is the use of both objective and subjective sleep 
parameters. Many studies rely only on self-reported measures, even though these 
measures often show differences with objectively measured sleep parameters 
[25,26]. Moreover, the PSQI and actigraphs are often used in sleep research, 
which makes it possible to compare the findings of this study to other studies. In 
addition, the EPDS is a validated tool in peripartum research worldwide and is 
suited to measure symptoms over a period of time. Finally, to our knowledge, this 
is the first study that studied the effects of both objective and subjective sleep 
quality on depressive symptoms in pregnant women with a psychiatric disorder. 
This study also has various limitations. First, we studied a relatively small number 
of patients and are therefore underpowered, which makes it difficult to generalize 
the findings of this study. Moreover, we measured sleep quality at the start of the 
study and did not measure this at follow up. Studying both depressive symptoms 
and sleep quality longitudinally might be more suited to study how these affect 
each other and to understand the causality. Therefore, we do not know how sleep 
quality changed over time and affected depressive symptoms. Third, we measured 
sleep quality for one week, which is a short time period and could have been 
influenced by external factors. A longer time period would have limited this 
possibility. Fourth, our data suffer from missing EPD scores. Possibly due to their 
mental disorder, the participants showed less motivation to fill out all 
questionnaires. This could have had influence on the robustness of our findings, 
especially regarding the final stage of pregnancy, and which could have 
underestimated the effect size. However, exploring missing data patterns did not 
show a selection of women with more missing EPDS assessments. While our 
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analysis did not give clear indication, we cannot rule out unmeasured factors 
influencing dropout. Finally, we studied a heterogeneous group of women with 
different mental disorders, which could have been affected differently by potential 
sleep problems. However, adjustment for diagnosis did not change our findings.  
 
Future directions 
For future research, it would be necessary to study more patients. In addition, it 
would be relevant to include pregnant women without a mental disorder as a 
reference group. Additionally, it would be interesting to assess sleep quality at 
different time points, preferably before pregnancy, in all 3 trimesters and 
postpartum, to gain more insight in how sleep quality changes through pregnancy 
and how this affects depressive symptoms in the peripartum period. In a 
longitudinal design, the reciprocal relation between sleep and depression may be 
better understood.  
 
Conclusions 
We explored if and how objectively and subjectively measured sleep parameters 
would be associated with antepartum depressive symptoms. Various sleep 
parameters were significantly correlated with EPDS scores when measured cross-
sectionally at the start. A number of sleep parameters had moderate to large 
effects on the course of depressive symptoms through the third trimester, but these 
effects were not statistically significant. More research is necessary to explore the 
causality of the direction between sleep problems and antepartum depressive 
symptoms we found in psychiatric patients. 
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This thesis discusses various aspects of antepartum depression, with a special 
focus on light, seasons and sleep. 
In Part I of this thesis, we first outlined the design of a randomized controlled trial 
(RCT) for evaluating the effectiveness of light therapy for depression during 
pregnancy. We subsequently presented the findings regarding our primary research 
question. In Part II, we focused on the seasonality of depressive symptoms during 
pregnancy. In Part III of this thesis, we focused on sleep during pregnancy. First, we 
examined the impact of sleep on depressive symptoms during pregnancy in 
psychiatric patients. In the next two chapters, we studied prescription patterns of 
benzodiazepines before, during and after pregnancy, which are often prescribed for 
sleep problems.  
Detailed descriptions on main results of the studies were discussed in the previous 
chapters. This chapter will provide a general discussion of all main findings, 
methodological considerations, clinical implications, implications for future research 
and a final conclusion. 
 
Part I – Light 
The Bright Up study 
In Chapter 2, we presented the detailed protocol of the Bright Up study, where we 
aimed to evaluate the effectiveness of bright light therapy (BLT) for pregnant women 
with a depressive disorder, compared to placebo. Earlier, two small RCTs showed 
significant improvement of depression among pregnant women exposed to BLT 
compared to placebo [1, 2]. Although these studies present promising results, the 
sample sizes of these studies are small and therefore, these studies are at risk for 
chance-findings [3]. In the Bright Up study, we aimed to investigate the effects of 
BLT on antepartum depression in a larger study sample, including follow up 
postpartum. 
In Chapter 3, we presented the findings regarding the primary research question of 
the Bright Up study, namely whether BLT is effective in treating depression during 
pregnancy. In this study, we randomized 67 pregnant women with depression to 
either BLT or dim red light therapy (DRLT). Although it is not known which of these 
two conditions is more effective, we hypothesize that the condition with DRLT could 
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be considered as biologically inactive and thus could be considered as placebo 
treatment [4]. Women received daily treatment with light of 30 minutes within 30 
minutes of habitual wake-up time for six weeks. Follow up took place weekly during 
the intervention period, at the end of the intervention period, three and ten weeks 
after treatment and at two months postpartum. In this study, we did not find a 
statistically significant difference between the two treatment arms during the 
intervention period nor during the entire study. Depression rating scale scores 
improved with 41.2-50% during the intervention period in the BLT group and with 45-
58.6% in the DRLT group.  
The improvement reported in the Bright Up study is comparable to that in the open 
study conducted among pregnant women with depression by Oren et al. [5] and the 
RCT conducted among postpartum women by Corral et al. [6], who both found an 
improvement of 49% in depression rating scale scores. Similar to our study, Corral 
et al. did not find superiority of BLT over placebo treatment. 
 
Effects in the Bright Up study 
The mean improvement in the placebo condition in the present study may be 
presented by placebo effects – which could also be the case in the group treated 
with BLT. A meta-analysis showed that the placebo response in antidepressant trials 
is approximately 68% [7]. However, this response has not been studied yet in light 
therapy studies specifically. 
Secondly, the improvement can be represented by non-specific treatment effects, 
such as “forcing” participants into a daily rhythm, which may benefit their symptoms 
[8], interaction with researchers or increased awareness and self-care by 
participating in a study. Noteworthy, Corral et al. reported that women enjoyed 30 
minutes of “quiet time”, which is reported by several of our participants as well. This 
quiet time could represent a form of relaxation or even mindfulness, which has been 
shown to be effective for a variety of psychological problems [9, 10]. Beneficial 
effects of mindfulness have also been shown for pregnant women specifically [11, 
12]. Moreover, an earlier systematic review discussing studies in treating antepartum 
depression, which all included a control condition, showed that a considerable 
improvement can be observed in both treatment arms [13]. In these control 
conditions, women received various treatments depending on the experimental 
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condition, such as treatment as usual, placebo light, non-specific acupuncture or 
they were put on a waiting list. 
Finally, the improvement in both groups may be represented by the course of 
pregnancy, spontaneous remission or regression to the mean. A meta-analysis has 
shown that untreated depressive symptoms could decrease by 10-15% over 2-20 
weeks [14]. However, leaving antepartum depression untreated is not advised, since 
untreated antepartum depression may eventually lead to postpartum depression 
[15], which in its turn might negatively impact the mother-child relationship [16].  
 
Discrepancy with earlier studies 
However, our findings differ from the studies by Epperson et al. [1] and Wirz-Justice 
et al. [2], who both found superiority of BLT over placebo treatment among pregnant 
women diagnosed with depression. Wirz-Justice et al. included only clinical 
outpatients and found that BLT had more effects in severe patients in their study. 
However, the baseline severity of depressive symptoms in the patients in our study 
did not differ clinically relevant from the study by Epperson et al. and Wirz-Justice et 
al. Additionally, sensitivity and post-hoc analyses showed that baseline severity did 
not change our findings.  
Both studies by Epperson et al. and Wirz-Justice et al. have a different treatment 
protocol from the present study. In the Bright Up study, women were instructed to 
have 30 minutes of light therapy within 30 minutes of habitual wake-up time. In the 
studies by Epperson et al. and Wirz-Justice et al., this was one hour of light therapy 
within 10 minutes of habitual wake-up time. This difference in protocol may be an 
explanation for not finding statistical significance between the two groups in the 
present study, since more light exposure in the BLT group may be necessary. Thus 
far, no meta-analysis has been conducted yet studying the relation between different 
light exposure durations and depressive symptoms in non-seasonal depression. 
However, other studies – in non-pregnant populations – showed a statistically 
significant difference between the active and placebo condition with a similar 
treatment protocol as in the present study [4]. 
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Future research 
We intended to include 150 participants, expecting a difference of 10-15% in 
depressive symptoms between the two groups, which would reflect a small to 
medium effect. Due to a lack of resources, we decided to stop the inclusion after 67 
inclusions. Despite this, we are internationally the largest RCT studying the effects 
of BLT on depression during pregnancy. Post-hoc power calculations showed us that 
this sample size would be sufficient to estimate a 15-20% difference in symptom 
reduction between the two conditions, which would reflect to a medium effect.  
For future research, it would not only be relevant to study a larger study sample to 
assess more subtle effects, but also to study whether the effects found in both 
treatment groups represent true treatment effects, non-specific treatment effects, 
placebo effects or a combination hereof. This could be done by studying biological 
outcomes, such as melatonin and cortisol levels. In the introduction of this thesis, 
the hypothalamus-pituitary-adrenal gland (HPA) axis and its role in regulating cortisol 
has been explained. The suprachiasmatic nucleus (SCN), also known as the 
‘biological clock’, controls the HPA axis: decreased inhibitory control of the SCN has 
been associated with HPA axis hyperactivity [17]. Since light synchronizes the SCN 
with the environmental circadian rhythm and thus influences the HPA axis, it may 
indirectly influence cortisol levels. The SCN does not only control the circadian 
rhythm of cortisol, but also that of melatonin [18-20]. Therefore, analyzing cortisol 
and melatonin levels may possibly show a statistically significant difference between 
the two treatment arms, regardless of perceived depressive symptoms. Urine, saliva 
and hair were collected at multiple time points in the Bright Up study, which would 
enable us to execute these analyses in the future. Due to limiting resources, we 
could not analyze these samples yet. 
 
Clinical implications 
In the Bright Up study, both treatment arms showed a major improvement in 
depressive symptoms. Considering this major improvement and considering the 
long-standing evidence on the efficacy of BLT on non-seasonal depression, amongst 
others shown by a Cochrane review [4] and two more recent meta-analyses [21, 22], 
it would be meaningful to implement light therapy in clinical practice in treating 
antepartum depression. Besides the beneficial effects on depressive symptoms 
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during pregnancy, participants experienced only mild adverse effects (e.g. headache 
for a maximum of three days) and found the treatment highly acceptable. Despite 
the fact that the placebo condition was just as effective in treating antepartum 
depressive symptoms as the experimental condition, light therapy would be an 
alternative treatment for psychotherapy and antidepressant medication, given the 
major improvement in a short time period, the high acceptability, the mild and short-
lived side effects, the low costs and the direct availability. 
 
Part II – Seasons 
Seasons and depression 
BLT has been an effective treatment for non-seasonal depression [4], but was first 
applied as treatment for seasonal affective disorder (SAD). In 1984, the first cases 
of SAD were described by Rosenthal et al. [23] as “a syndrome characterized by 
recurrent depressions that occur annually at the same time each year”. Together 
with a description of the first SAD cases, they presented their preliminary findings on 
treatment with BLT. More recently, seasonal variation has also been found in 
pregnant [24] and postpartum women [25-30]. 
In order to study whether seasons might influence depressive symptoms during 
pregnancy and with that possibly the treatment with light therapy in the Bright Up 
study, we studied seasonal variability in these symptoms in a cross-sectional study 
in Chapter 4. In a large observational cohort, pregnant women were screened on 
psychopathology, psychosocial problems and substance use. Amongst others, data 
was collected on current depressive symptoms. We fitted a sinusoidal curve to the 
data to estimate the seasonal relationship between month of assessment and 
antepartum depressive symptoms. In the entire study sample, we did not find any 
evidence for seasonal influences on depressive symptoms during pregnancy, after 
adjustment for confounders. We did find that current treatment status obscured the 
seasonal influences. In our study, there were two distinct groups with opposite 
effects, which eventually resulted in not finding any effects in the total study sample. 
In women untreated for psychiatric complaints, a minimum of depressive 
symptomatology was found in September and a maximum in March. In women 
treated for psychiatric complaints, a minimum of depressive symptomatology was 
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found in December and a maximum in June. Thus, seasonal influences on 
depressive symptoms during pregnancy can be observed, but are different in women 
treated or untreated for psychiatric problems. In Chapter 4, we speculated on 
possible explanations for these findings, such as meteorological and social factors. 
For example, we speculated that women treated for psychiatric problems, who are 
possibly more in need of social support, might experience less of this support in 
summer, when family, neighbors and caregivers are gone for vacation, which might 
exacerbate their depressive symptoms. 
 
Seasons and the Bright Up study 
The findings of this part of the thesis suggested that seasons influence depressive 
symptoms during pregnancy and subsequently, we hypothesized that seasons might 
possibly influence the treatment effect in the Bright Up study. Therefore, we adjusted 
the analyses in the Bright Up study for when women were treated for their depressive 
symptoms. Possibly, treatment with BLT in winter may be more effective than 
treatment in summer compared to placebo treatment, for example. However, 
sensitivity analyses where we adjusted for when women were treated, did not 
change our findings (see Chapter 3). Thus, seasonal influences did not seem to 
impact the effects of light therapy in the Bright Up study. 
Since the effect of current treatment status modified the seasonal influences on 
depressive symptoms in Chapter 4, we repeated the primary analyses in Chapter 
3, adjusted for not only current treatment status, but also for any treatment 
intervention besides the treatment with light women received in the study. However, 
these sensitivity and post-hoc analyses did not change our findings in the Bright Up 
study as well. 
One major limitation of Part II is that the study of Chapter 4 is conducted in a cross-
sectional design. This design may be less suitable to study the seasonality of 
depressive symptoms during pregnancy, since seasonal influences are possibly 
experienced as an intra-individual course. In the Bright Up study, it would be possible 
to study seasonal variations not only between women, but also within women, due 
to the longitudinal design. However, in these women, treatment with light therapy 
might change depressive symptoms and with that, any potential seasonal variation. 
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Future research 
For future research, it is important to study the prevalence and severity of depressive 
symptoms during pregnancy longitudinally, which would allow to follow patients 
across various seasons. Since women treated for psychiatric problems showed a 
seasonal pattern different from the general population, it would be relevant for both 
researchers and clinicians to study the underlying causes for these divergent 
findings. Additionally, it would be important to study how seasons impact the start 
and the length of the depressive episode and treatment hereof. Finally, in Chapter 
4, we found that age, ethnicity and educational level emerged as confounders in the 
relationship between month of assessment and depressive symptoms. Therefore, 
we hypothesized that these socio-demographic factors are related to the planning of 
pregnancy. It would be interesting for future studies to explore this hypothesis.  
 
Clinical implications 
The present study showed that depressive symptoms during pregnancy are 
prevalent year round. Moreover, seasonal influences may be experienced differently 
by different women, which may actually lead to more depressive symptoms in spring 
and summer for particular subgroups of women. Additionally, in the Bright Up study 
(Chapter 3), we received referrals from participants the entire year through. 
Therefore, health care professionals should be aware of antepartum depressive 
symptoms not only during autumn and winter, but also during spring and summer. 
 
Part III – Sleep 
Sleep quality and depressive symptoms 
Since BLT has a great effect on sleep and with that on mood [31], we dedicated Part 
III to sleep. First, in Chapter 5, we studied sleep quality in pregnant women with a 
mental disorder. Poor sleep quality during pregnancy is associated with both 
antepartum and postpartum depressive symptoms [32-36]. However, many studies 
only studied self-reported measures, while subjective sleep quality is worse than 
objective sleep quality in pregnant women with a mental disorder [37]. Studies with 
objective measurements of sleep have thus far been conducted in healthy women 
only [32, 36, 38], which cannot be extrapolated to pregnant women with a mental 
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disorder. This is relevant, since these women are not only at risk for sleep problems 
because of their pregnancy, but also because of their mental problems. Therefore, 
we studied in Chapter 5 the effects of both objective and subjective sleep quality on 
depressive symptoms in pregnant women in an explorative study of 18 psychiatric 
patients. Here, we found that various objective and subjective sleep parameters 
indicating decreased sleep quality (e.g. various subscales of the Pittsburgh Sleep 
Quality Index) were associated with depressive symptoms when measured cross-
sectionally. A number of objective and subjective sleep parameters (e.g. total sleep 
time measured by diary and actigraph) had moderate to large effects on the course 
of depressive symptoms, both positive and negative, but these were not statistically 
significant.  
A limitation of this study is the small sample size. Because of this small study sample, 
we are only powered to find large effects, which makes it difficult to draw stringent 
conclusions regarding the findings of this study. More research in larger study 
samples would be necessary to explore the causality of the direction between sleep 
problems and depressive symptoms in this particular group of patients. A second 
limitation of Chapter 5 is that we measured sleep quality at the start of the study and 
did not measure this at follow up. For future studies, it would be interesting to 
measure both sleep quality and depressive symptoms in a longitudinal design, 
preferably before pregnancy, in all three trimesters and in the postpartum period, to 
gain more insight in how sleep quality and depressive symptoms change in the 
peripartum period and how these affect each other.  
 
Clinical implications 
The present study adds to the existing evidence that sleep problems during 
pregnancy are associated with depressive symptoms. Therefore, clinicians should 
be aware of potential sleep problems in pregnant patients and should make an effort 
in improving sleep quality during pregnancy. 
 
Sleep quality and the Bright Up study 
In the Bright Up study, we collected data on both objective and subjective sleep 
quality and depressive symptoms longitudinally, not only during pregnancy, but also 
at two months postpartum (see for more details Chapter 2). For this thesis, these 
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results have not been analyzed yet. Since sleep problems are common in pregnancy 
[39, 40] and depressive symptoms are associated with sleep problems both during 
and after pregnancy [32-36], we expect that many women experienced sleep 
problems in the Bright Up study. For future research, we will study the same objective 
and subjective sleep parameters as in Chapter 5, to validate these findings. In 
addition, we will study more objective sleep parameters, such as intradaily and 
interdaily variability. Since we will study these sleep parameters together with 
depressive symptoms in a longitudinal design, we might find different associations. 
Also, women will be treated for their depressive symptoms with light therapy, which 
might reveal different associations.  
The Bright Up study did not show a significant difference in depressive symptoms 
between the two treatment arms (Chapter 3), but since BLT has a tremendous effect 
on sleep [31], we may find statistically significant differences in sleep parameters 
between the two treatment arms. Earlier, a systematic review and meta-analysis 
showed that light therapy may be effective in treating sleep problems in general [41]. 
If would BLT alleviate sleep problems during pregnancy, it would provide a non-
pharmacological alternative treatment for sleep medication, without adverse effects 
for the fetus.  
 
Sleep medication in the peripartum period 
Sleep problems are very common during pregnancy [39, 40] and may be treated 
pharmacologically with benzodiazepines [42]. In a population-based cohort study 
(Chapter 6), we found that the majority of benzodiazepines prescriptions in the 
peripartum period were prescribed for sleeping problems. The use of 
benzodiazepines during pregnancy is approached with caution, considering the 
potential harmful (fetal) effects on one hand, but also considering maternal health on 
the other hand. Despite this caution, the use of benzodiazepines [43] and 
benzodiazepine-related drugs [44] has increased in the past decades, a trend we 
have observed with prescription drugs in general [45-47]. 
In this part of the thesis, we studied, next to the effects of sleep quality on depressive 
symptoms during pregnancy, the use of benzodiazepines before, during and after 
pregnancy. In Chapter 6, we studied prescription patterns of benzodiazepines and 
benzodiazepine-related drugs in a population-based study cohort in Denmark, where 
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we studied 1,154,817 pregnancies from 1997 to 2015. Here, we found a prevalence 
of 1.9% before pregnancy, of 0.6% during pregnancy and of 1.3% after pregnancy. 
In women with a psychiatric history before pregnancy, the prevalence of 
benzodiazepine prescriptions was five to six times higher, compared to women with 
no psychiatric history. We found that, contrary to earlier studies [43-47], prescription 
prevalence rates of benzodiazepines before, during and after pregnancy decreased 
in the past years. Additionally, a higher percentage of women discontinuing 
benzodiazepines during pregnancy was observed from 1997 to 2015.  
Possibly, these observations are caused by changed treatment guidelines. Next to 
sleep problems, benzodiazepines are often prescribed for the treatment of anxiety 
disorders [42], which was also shown in Chapter 6. Patients suffering from anxiety 
disorders were often treated with benzodiazepines, but recent guidelines advise 
against that [48]. Therefore, these patients are treated more often with 
antidepressants instead of benzodiazepines [49, 50], which could explain the 
decrease in benzodiazepine prescriptions we have observed in this study. 
Additionally, the observed decrease in the past years may be driven by various 
studies reporting on the adverse fetal effects following benzodiazepine exposure in 
utero [51-54], which may have increased awareness among women and their 
physicians.  
 
International exposure to sleep medication 
The study of Chapter 6 was conducted in Denmark and may therefore not be 
representative for other countries. Therefore, in Chapter 7, we conducted a 
systematic review and meta-analysis where we studied the prevalence of 
benzodiazepine exposure before, during and after pregnancy worldwide. Here, 
studying 7,343,571 pregnancies from 28 countries, we found a prevalence of 0.9% 
before pregnancy, of 1.9% during pregnancy and of 0.5% after pregnancy. We found 
that the prevalence was highly dependent on trimester, the type of benzodiazepine 
and country. For example, the highest prevalence of benzodiazepine use was found 
in Eastern Europe (14.0%), whereas the lowest prevalence was found in Asia (0.9%). 
Additionally, the prevalence was greatly influenced by study characteristics. Among 
the different studies, substantial heterogeneity was found. 
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When we pooled all prevalence data on benzodiazepine use during pregnancy in 
Northwestern Europe, a higher prevalence was found in this meta-analysis (1.2%), 
compared to the population-based study we conducted in Denmark (0.6%). A major 
difference between these two studies is the definition of benzodiazepine exposure. 
In the systematic review and meta-analysis, we included all studies reporting on 
benzodiazepine prevalence, including prescription studies as in Chapter 6, but also 
including studies determining prevalence from self-report and body samples. 
Sensitivity analyses in the meta-analysis showed a significant difference in 
benzodiazepine prevalence when using different definitions for benzodiazepine 
exposure. We found that the pooled prevalence of benzodiazepine use was lower 
when studies used prescription records as a proxy for benzodiazepine use, 
compared to when women reported their benzodiazepine use. This is in accordance 
with the lower prevalence in the Danish population-based study in Chapter 6, which 
is based on registry data. Still, registry data may overestimate actual medication use 
due to non-compliance. A higher prevalence reported by self-report compared to 
prescription data may be explained by the fact that women sporadically use 
medication from others. A Dutch study among the general population showed that 
approximately 13% obtained prescription drugs through non-formal channels, with 
sleeping medication being one of the most frequently obtained [55]. However, 
underestimation could still play a role here, when women do not admit to or are 
ashamed of using prescription drugs during pregnancy [56]. 
 
Change over time in exposure 
As earlier mentioned, we found a decrease in benzodiazepine prescription rates from 
1997 to 2015 in Chapter 6, which is in contrast to two earlier studies, reporting an 
increase in benzodiazepine and benzodiazepine-related drug exposure in the past 
years [43, 44]. In Chapter 7, we tried to study the prevalence rates over time. Here, 
we could not find a significant change over time during pregnancy. There were 
unfortunately not enough studies to conduct these analyses in the year before 
pregnancy or the year following pregnancy. Therefore, we cannot draw stringent 
conclusions regarding the prevalence rates over time in the systematic review and 
meta-analysis. 
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Use of sleep medication in this thesis 
In Chapter 5, where we studied the effects of sleep on depressive symptoms during 
pregnancy, none of the participants reported any benzodiazepines or 
benzodiazepine-related drugs. Therefore, we cannot study the effects of these drugs 
on their sleep or depressive symptoms. In the Bright Up study (Chapter 3), we 
collected information on the use of any sleep-promoting medications and 
supplements. However, only four women reported on the sporadic use of 
benzodiazepines. Sensitivity analyses, where we could study the effects of the use 
of benzodiazepines on depressive symptoms during pregnancy, were therefore not 
justified.  
 
Future research 
From Chapters 6 and 7, we can conclude that the use of benzodiazepines during 
pregnancy is prevalent, despite the considerable heterogeneity among studies. 
Given the substantial proportion of children exposed to benzodiazepines in utero, it 
is relevant for future studies to continue to focus on the safety of maternal 
benzodiazepine use during pregnancy. Most studies have focused on short-term 
effects of fetal exposure to benzodiazepines [51-54], long-term effects are however 
not entirely clear [57]. Studies of sound methodological quality are necessary in order 
to provide reliable and evidence-based information in complex treatment decisions. 
However, women and clinicians should carefully weigh both the maternal health and 
the potential teratogenic risk known from recent literature when considering 
benzodiazepine treatment, a decision that is different for every individual. Further, 
future studies should continue to explore non-pharmacological alternative 
treatments, such as light therapy [41]. 
 
Clinical implications 
Both Chapter 6 and Chapter 7 showed that benzodiazepine use is relatively 
common during pregnancy, with large variations across countries. Considering the 
relatively common prevalence with potential risks for both mother and (unborn) 
infant, this is worrying and calls for prescription guidelines in the preconception 
period. Moreover, both women and clinicians should be better informed about 
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potential adverse outcomes, particularly as self-treatment is common among 
pregnant women. 
 
Summary of clinical and research implications 
The studies in this thesis provide the following clinical and research implications: 
 In Chapter 3, we found no superiority of BLT over DRLT in pregnant women 
with a depressive disorder. Both groups showed improvement in depressive 
symptoms during six weeks of light treatment. Given the very mild and short-
lived side effects, the major improvement in a short time period, the high 
acceptability of the participants, the low costs and the direct availability, and 
considering the long-standing evidence of the beneficial effects of BLT on non-
seasonal depression, light therapy should be implemented in clinical practice in 
treating antepartum depression. 
 More studies to the effectiveness of BLT during pregnancy are warranted. It is 
important to determine whether the responses observed in the Bright Up study 
(Chapter 3) represent true treatment effects, non-specific treatment effects or 
placebo effects. This may be done by studying biological measures, such as 
melatonin and cortisol levels. 
 In the Bright Up study (Chapter 3), we received referrals from pregnant women 
with depressive symptoms all year round. Chapter 4 showed that depressive 
symptoms are not only present during autumn and winter, but also during spring 
and summer. Also, seasonal influences are experienced differently in different 
groups of pregnant women, which may even lead to more depressive symptoms 
during summer for particular subgroups of pregnant women. These findings 
indicate that health professionals should be aware of antepartum depressive 
symptoms the whole year through.  
 Women whom were treated for psychiatric problems showed a seasonal pattern 
different from the general population, with a peak in depressive symptoms during 
summer (Chapter 4). For future research, it would be relevant to study the 
underlying causes for these divergent findings. 
 Clinicians should be aware of sleep problems in pregnant patients, for these are 
highly prevalent and they are associated with depressive symptoms (Chapter 
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5). Therefore, an effort should be made in improving sleep quality during 
pregnancy. 
 We found that various objective and subjective sleep parameters are associated 
with depressive symptoms in an explorative study of pregnant women with a 
mental disorder (Chapter 5). More research would be necessary in this 
vulnerable group of patients to explore the causality of the direction between 
sleep problems and depressive symptoms. This is relevant, since these women 
are at risk for sleep problems, not only because of their pregnancy, but because 
of their mental disorder as well. 
 In Chapter 6, we observed that prescription prevalence rates of 
benzodiazepines and benzodiazepine-related drugs decreased in the past 
decades. Additionally, more women discontinued these drugs during pregnancy. 
This may be due to changed treatment guidelines in the treatment of anxiety 
disorder. Secondly, this decrease may be driven by increased awareness due to 
various studies reporting on adverse effects for the fetus and the neonate. 
 In our systematic review and meta-analysis (Chapter 7), we found that the use 
of benzodiazepines during pregnancy differed greatly between countries. The 
highest prevalence was found in Eastern Europe, whereas the lowest 
prevalence was found in Asia. These differences may reflect differences in the 
prevalence and/or severity of mental health problems, but could also be due to 
differences in national guidelines, prescribing behavior of physicians, available 
medical facilities and beliefs of the general population. 
 We found in Chapter 6 and 7 that benzodiazepine use during pregnancy is 
prevalent. Therefore, it is relevant for future research to focus on not only the 
short-term safety of maternal benzodiazepine use for the fetus, but also the long-
term safety of in utero benzodiazepine exposure, which is not entirely clear at 
this point. More research is necessary to provide reliable and evidence-based 
information, which could potentially guide treatment decisions for both women 
and their physicians. Further, future research should continue to explore non-
pharmacological alternatives for treating sleep problems during pregnancy, such 
as light therapy. 
 Self-treatment with benzodiazepines is relatively common during pregnancy 
(Chapter 7). Considering the potential risks for both mother and infant 
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associated with benzodiazepine use during pregnancy, this is a worrying finding 
and calls for prescription guidelines in the preconception period. 
 
Final conclusions 
Depression during pregnancy is prevalent year round. A randomized controlled trial 
in pregnant women with a depressive disorder showed that both bright light therapy 
and placebo treatment improved depressive symptoms. We found that various 
objective and subjective sleep parameters were associated with depressive 
symptoms during pregnancy. Sleep problems are very common during pregnancy, 
which may be treated pharmacologically with benzodiazepines. International 
differences in benzodiazepine exposure have been observed in women before, 
during and after pregnancy. However, a decrease in benzodiazepine prescriptions 
in the last years seems to be present. 
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Depression during pregnancy is common with a prevalence of around 12%. 
Guidelines propose psychotherapy, antidepressant medication or a combination of 
both as treatment. However, in clinical practice the applicability of these treatments 
during pregnancy is limited, which makes it urgent to investigate alternative 
approaches in treating antepartum depression, such as light therapy. Earlier, two 
studies in pregnant women suggested beneficial effects of light therapy, but the 
sample sizes of these studies were small. Therefore, in Chapter 2, we outlined the 
design of a randomized controlled trial (RCT) for evaluating the effectiveness of light 
therapy for depression during pregnancy: the Bright Up study. In the Bright Up study, 
we aimed at including 150 pregnant women with a gestational age of 12-18 weeks 
with a diagnosis of depressive disorder. Women received either treatment with bright 
light therapy (BLT) or dim red light therapy (DRLT). Although it is not known which 
of these two conditions is most effective, we hypothesize that the DRLT condition 
could be considered as placebo condition. Both groups were treated daily for 30 
minutes upon awakening for six weeks at home. Several follow up measurements 
during and after pregnancy took place at fixed points in time. The primary outcome 
of the trial was symptoms of depression. Secondary outcomes included maternal 
sleep quality (both objective and subjective), maternal hormonal levels and birth and 
child outcomes. We hypothesized that daily treatment with BLT would improve 
depressive symptoms during pregnancy. Additionally, we hypothesized that this 
improvement would be accompanied by improved sleep quality, lower basal cortisol 
levels and normalized melatonin levels. Finally, we hypothesized that birth and child 
outcomes would be better in women treated with BLT, compared to women treated 
with DRLT. 
 
In Chapter 3, we reported the findings regarding our primary research question of 
the Bright Up study. For this study, 67 pregnant women were included between 12 
and 32 weeks of pregnancy. Depressive symptoms were primarily measured with 
the Structured Interview Guide for the Hamilton Depression Scale – Seasonal 
Affective Disorder (SIGH-SAD). Secondary measures were the 17-item Hamilton 
Rating Scale for Depression (HAM-D) and the Edinburgh Postnatal Depression 
Scale (EPDS). Follow up took place weekly during the intervention period, at the end 
of the intervention period, three and ten weeks after treatment and at two months 
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postpartum. Depression rating scale scores improved with 41.2-50% during the 
intervention period in the BLT group and with 45.0-58.6% in the DRLT group. We did 
not find a statistically significant difference between the two treatment arms during 
the intervention period nor during the entire study. More research is needed to 
determine whether these responses represent true treatment effects, non-specific 
treatment responses, placebo effects or a combination of these. 
 
In Chapter 4, we studied the seasonal influences on depressive symptoms during 
pregnancy. Data of 2,438 pregnant women on current depressive symptoms was 
collected in a large-scale cross-sectional study. Depressive symptoms were 
assessed using the EPDS and dichotomized using ≥ 9 as cut-off score. The 
relationship between depressive symptoms during pregnancy and the month of 
assessment was estimated by fitting a sinusoidal curve to the data. In the full sample, 
after adjusting for confounders, we found no significant evidence for seasonal 
influences on depressive symptoms. We found that the seasonal influence was 
obscured by current treatment status for psychiatric complaints. In untreated women, 
we found a minimum of depressive symptomatology in September and a maximum 
in March. In women treated for psychiatric symptoms, we found a minimum of 
depressive symptomatology in December and a maximum in June. Thus, the effects 
of seasonality are apparent, but opposite in women treated and untreated for 
psychiatric complaints. However, health professionals should be aware of 
depressive symptoms during pregnancy the whole year through. 
 
We evaluated both objective and subjective sleep quality and the effects on the 
subsequent course of antepartum depressive symptoms in psychiatric patients in 
Chapter 5. For this study, we included 18 pregnant (24-29 weeks) patients with a 
mental disorder. Depressive symptoms were assessed with five-week intervals 
throughout pregnancy using the EPDS. Both objective and subjective sleep 
parameters were assessed. Various objective and subjective sleep parameters 
pointing at decreased sleep quality were significantly correlated with depressive 
symptoms when measured cross-sectionally at baseline. Six objectively and 
subjectively measured sleep parameters had moderate to large effects, both positive 
and negative, on the course of depressive symptoms through the third trimester, but 
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these effects were not statistically significant. More research is necessary to explore 
the causality of the direction between sleep problems and antepartum depressive 
symptoms in psychiatric patients. 
 
In Chapter 6, we studied prescription patterns of benzodiazepines and 
benzodiazepine-related drugs before, during and after pregnancy in a population-
based study in Denmark. Here, we studied 1,154,817 pregnancies between 1997 
and 2015, of which 205,406 (17.8%) pregnancies in women with a psychiatric 
history. The prevalence of benzodiazepine prescriptions was 1.9% before 
pregnancy, 0.6% during pregnancy and 1.3% after pregnancy. In women with a 
psychiatric history, the prevalence was five to six times higher. From 1997 to 2015, 
we observed a significant decrease in prescriptions before, during and after 
pregnancy, which was more profound among women with a psychiatric history. 
Approximately 90% of women discontinue benzodiazepines during pregnancy, with 
a higher percentage of women discontinuing over time, especially women with a 
psychiatric history. Possibly, these observations are caused by changed treatment 
guidelines for the treatment of anxiety disorder. 
 
In Chapter 7, we conducted a systematic review and meta-analysis, where we 
studied the literature to measure the worldwide use of benzodiazepine use before, 
during and after pregnancy. We identified 32 studies reporting on 28 countries, 
together reporting on 7,343,571 pregnancies. Here, we found a prevalence of 0.9% 
before pregnancy, of 1.9% during pregnancy and of 0.5% after pregnancy. We found 
that the prevalence was highly dependent on trimester, the type of benzodiazepine 
and country. Prevalence was highest in the third trimester. Lorazepam was most 
often prescribed. Highest prevalence was found in Eastern Europe. Also, the 
prevalence was influenced to a great extent by characteristics of the study. Despite 
substantial heterogeneity, our meta-analysis confirmed that benzodiazepine use 
before, during and after pregnancy is prevalent worldwide. We did not find a 
significant change over time in benzodiazepine use during pregnancy. Given the 
substantial proportion of children exposed to benzodiazepines in utero, future 
research should further study the safety of maternal benzodiazepine use during 
pregnancy, both on short and on long-term effects. 
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Main findings and conclusions of this thesis, together with methodological 
considerations, implications for future research and a final conclusion, are reported 
in Chapter 8. First, we concluded that light therapy should be implemented in clinical 
practice in treating antepartum depression. Second, more research on the effects of 
BLT in the treatment of depression during pregnancy is needed. Third, health 
professionals should be aware of depressive symptoms during pregnancy the whole 
year through. For future research, it would be interesting to study the underlying 
causes for the high prevalence of depressive symptoms in summer in specific 
subgroups of pregnant women. Next, we concluded that clinicians should be aware 
of sleep problems in pregnant patients with a mental disorder and that more research 
on sleep needs to be conducted in this particular group of patients. Moreover, we 
observed that the number of benzodiazepine prescriptions has decreased in the past 
years. Also, we concluded that the use of benzodiazepines differed greatly between 
countries. In future studies, both short-term and long-term effects of in utero 
benzodiazepine exposure should be studied.  Finally, prescription guidelines for 
benzodiazepines in the preconception period are necessary. 
 
 
Nederlandse samenvatting 
 
 
  
240 
 
Depressie tijdens de zwangerschap komt regelmatig voor met een prevalentie van 
ongeveer 12%. Richtlijnen stellen psychotherapie, antidepressieve medicatie of een 
combinatie voor bij de behandeling hiervan. Echter, de klinische praktijk wijst uit dat 
deze behandelingen hun beperkingen hebben tijdens de zwangerschap, wat de 
urgentie van het onderzoeken van alternatieve benaderingen in het behandelen van 
antepartum depressie onderstreept, zoals lichttherapie. Twee eerdere studies onder 
zwangere vrouwen lieten gunstige effecten van lichttherapie zien, maar de 
steekproefgroottes van deze studies waren klein. Daarom hebben wij in Hoofdstuk 
2 het protocol van een gerandomiseerde klinische studie geschetst, waarin de 
effecten van lichttherapie voor depressie tijdens de zwangerschap worden 
geëvalueerd: de Bright Up studie. In de Bright Up studie streefden we ernaar om 150 
vrouwen te includeren met een zwangerschapsduur van 12-18 weken en 
gediagnosticeerd met een depressieve stoornis. Vrouwen werden ofwel behandeld 
met “bright light therapy” (BLT) of “dim red light therapy” (DRLT). Hoewel het niet 
bekend is welke van deze twee condities het meest effectief is, was onze hypothese 
dat de DRLT-conditie kan worden beschouwd als placebo. Beide groepen werden 
thuis dagelijks 30 minuten lang behandeld na het ontwaken gedurende 6 weken. 
Verscheidende follow-up metingen tijdens en na de zwangerschap volgden tijdens 
vaste momenten. De primaire uitkomst was symptomen van depressie. Secundaire 
uitkomsten waren maternale slaapkwaliteit (zowel objectief als subjectief), maternale 
hormonale spiegels en geboorte- en kinduitkomsten. Onze hypothese was dat de 
dagelijkse behandeling met BLT depressieve symptomen tijdens de zwangerschap 
zou verminderen. Daarnaast verwachtten we dat deze verbetering gepaard zou 
gaan met een betere slaapkwaliteit, lagere basale cortisolspiegels en 
genormaliseerde melatoninespiegels. Tenslotte was onze hypothese dat geboorte- 
en kinduitkomsten gunstiger zouden zijn in de vrouwen die behandeld waren met 
BLT, vergeleken met de vrouwen die behandeld waren met DRLT. 
 
In Hoofdstuk 3 hebben we de bevindingen van onze primaire onderzoeksvraag 
binnen de Bright Up studie beschreven. Voor dit onderzoek werden 67 vrouwen 
geïncludeerd tussen 12 en 32 weken zwangerschap. Depressieve symptomen 
werden primair gemeten met de Structured Interview Guide for the Hamilton 
Depression Scale – Seasonal Affective Disorder (SIGH-SAD). Secundaire metingen 
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waren de 17-item Hamilton Rating Scale for Depression (HAM-D) en de Edinburgh 
Postnatal Depression Scale (EPDS). Follow-up vond wekelijks plaats tijdens de 
interventie, aan het einde van de interventie, drie en tien weken na de interventie en 
twee maanden postpartum. Depressiescores verbeterden met 41,2-50% tijdens de 
interventie in de BLT-groep en met 45-58,6% in de DRLT-groep. We vonden in dit 
onderzoek geen statistisch significant verschil tussen de twee verschillende groepen 
gedurende de interventie noch tijdens de gehele studie. Meer onderzoek is nodig 
om te bepalen of deze effecten werkelijke behandelingseffecten zijn, aspecifieke 
behandelingseffecten, placebo-effecten of een combinatie hiervan. 
 
In Hoofdstuk 4 bestudeerden we de invloed van de seizoenen op depressieve 
symptomen tijdens de zwangerschap. Data van 2.438 vrouwen over huidige 
depressieve symptomen werden verzameld in een grootschalig cross-sectioneel 
onderzoek. Depressieve symptomen werden gemeten met de EPDS, welke werd 
gedichotomiseerd met ≥ 9 als drempelwaarde. De relatie tussen antepartum 
depressieve symptomen en de maand van dataverzameling werd geschat door een 
sinusvormige curve in de data te laten passen. We vonden in de complete 
onderzoekspopulatie geen significant bewijs voor invloed van de seizoenen op 
depressieve symptomen, na het corrigeren voor andere factoren die deze relatie 
mogelijk zouden kunnen verstoren. We vonden dat de seizoensinvloeden werden 
beïnvloed door de huidige behandeling van psychiatrische symptomen. We vonden 
bij onbehandelde vrouwen een minimum van depressieve symptomatologie in 
september en een maximum in maart. Bij vrouwen die behandeld werden voor 
psychiatrische klachten vonden we een minimum van depressieve symptomatologie 
in december en een maximum in juni. De effecten van seizoenen zijn dus aanwezig, 
maar tegengesteld in behandelde en onbehandelde vrouwen. Echter, 
zorgprofessionals zouden het gehele jaar bedachtzaam moeten zijn op depressieve 
klachten tijdens de zwangerschap. 
 
In Hoofdstuk 5 evalueerden we zowel objectieve als subjectieve slaapkwaliteit en 
de effecten hiervan op het verloop van antepartum depressieve symptomen in 
psychiatrische patiënten. Voor dit onderzoek includeerden we 18 zwangere (24-29 
weken) patiënten met een psychiatrische stoornis. Depressieve symptomen werden 
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gemeten met de EPDS gedurende de zwangerschap met intervallen van vijf weken. 
Zowel objectieve als subjectieve slaapparameters werden gemeten. Verscheidene 
objectieve en subjectieve slaapparameters wijzend op lagere slaapkwaliteit waren 
significant gecorreleerd met depressieve symptomen, wanneer deze cross-
sectioneel werden gemeten bij de start van het onderzoek. Zes objectief en 
subjectief gemeten slaapparameters hadden matige tot grote effecten, zowel positief 
als negatief, op het verloop van de depressieve symptomen tijdens het derde 
trimester, maar deze waren niet statistisch significant. Meer onderzoek is nodig om 
de causaliteit van de richting tussen slaapproblemen en antepartum depressieve 
symptomen te onderzoeken in psychiatrische patiënten. 
 
In Hoofstuk 6 hebben we voorschrijfpatronen van benzodiazepines en 
benzodiazepine-gerelateerde medicatie voor, tijdens en na de zwangerschap 
onderzocht in een populatie-gebaseerde studie in Denemarken. Hier bestudeerden 
we 1.154.817 zwangerschappen tussen 1997 en 2015, waarvan 205.406 (17,8%) 
zwangerschappen in vrouwen met een psychiatrische voorgeschiedenis. De 
prevalentie van benzodiazepinerecepten was 1,9% voor de zwangerschap, 0,6% 
tijdens de zwangerschap en 1,3% na de zwangerschap. De prevalentie was vijf tot 
zes keer hoger in vrouwen met een psychiatrische voorgeschiedenis. We vonden 
van 1997 tot 2015 een significante afname in recepten zowel voor, tijdens als na de 
zwangerschap, die sterker was in vrouwen met een psychiatrische 
voorgeschiedenis. Ongeveer 90% van de vrouwen stopt het gebruik van 
benzodiazepines tijdens de zwangerschap, met een hoger percentage vrouwen die 
stopt na verloop van tijd, voornamelijk vrouwen met een psychiatrische 
voorgeschiedenis. Mogelijkerwijs zijn deze observaties toe te schrijven aan 
veranderingen in richtlijnen in de behandeling van angststoornissen. 
 
In Hoofdstuk 7 voerden wij een systematische review en meta-analyse uit waarin 
wij de literatuur bestudeerden rond het wereldwijde gebruik van benzodiazepines 
voor, tijdens en na de zwangerschap. We identificeerden 32 artikelen rapporterend 
over 28 landen. Gezamenlijk rapporteerden deze artikelen over 7.343.571 
zwangerschappen. In onze meta-analyse vonden wij een prevalentie van 0,9% voor 
de zwangerschap, 1,9% tijdens de zwangerschap en 0,5% na de zwangerschap. We 
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vonden dat de prevalentie afhankelijk was van het onderzochte trimester, het type 
benzodiazepine en het land. De prevalentie was het hoogst in het derde trimester. 
Lorazepam werd het vaakst voorgeschreven. De hoogste prevalentie werd 
gevonden in Oost-Europa. Ook werd de prevalentie zeer beïnvloed door 
studiekarakteristieken. Ondanks aanzienlijke heterogeniteit bevestigde onze meta-
analyse dat het gebruik van benzodiazepines voor, tijdens en na de zwangerschap 
prevalent is wereldwijd. Over de tijd vonden we geen significant verschil in 
benzodiazepinegebruik tijdens de zwangerschap. Gezien het grote aantal kinderen 
dat in de baarmoeder wordt blootgesteld aan benzodiazepines, moeten toekomstige 
onderzoeken de veiligheid van het maternale gebruik van benzodiazepines blijven 
bestuderen, zowel de effecten op de korte termijn als op de lange termijn. 
 
De belangrijkste bevindingen en conclusies van dit proefschrift zijn samen met 
methodologische overwegingen, implicaties voor toekomstig onderzoek en een 
eindconclusie gepresenteerd in Hoofdstuk 8. Ten eerste concludeerden wij dat 
lichttherapie zou moeten worden geïmplementeerd in de klinische praktijk bij de 
behandeling van antepartum depressie. Ten tweede is meer onderzoek naar de 
effecten van BLT bij de behandeling van depressie tijdens de zwangerschap nodig. 
Ook moeten zorgprofessionals het hele jaar bedachtzaam zijn op depressieve 
klachten tijdens de zwangerschap. Voor vervolgonderzoek zou het interessant zijn 
om de onderliggende oorzaken van de hoge prevalentie van depressieve 
symptomen in de zomer bij specifieke subgroepen zwangere vrouwen te 
onderzoeken. Vervolgens concludeerden we dat clinici alert zouden moeten op 
slaapproblemen bij zwangere vrouwen met een psychiatrische stoornis en dat meer 
onderzoek naar slaap nodig is bij deze specifieke groep van patiënten. Ook hebben 
we geobserveerd dat het aantal benzodiazepinerecepten in de afgelopen jaren zijn 
afgenomen. Daarnaast observeerden we sterke verschillen tussen landen in het 
gebruik van benzodiazepines. In toekomstige onderzoeken moeten zowel 
kortetermijn- als langetermijneffecten van blootstelling in de baarmoeder aan 
benzodiazepines onderzocht worden. Tenslotte, richtlijnen voor het gebruik van 
benzodiazepines in de preconceptie periode zijn nodig. 
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